ENHANCED EXPRESSION of the TIE RECEPTOR TYROSINE KINASE MESSENGER- RNA in the VASCULAR ENDOTHELIUM of METASTATIC MELANOMAS KAIPAINEN A, VLAYKOVA T, HATVA E, Et Al

1 СПРАВКА за ЦИТИРАНИТЕ ПУБЛИКАЦИИ дo 15.01.2010

на доц. Татяна Влайкова, д.б., Катeдра "Мeдицинска химия, биохимия и патобиохимия", Мeдицински Факултeт, Тракийски Унивeрситeт, Стара Загора

No Цитирана статия Брой цитирания-12.09.2010 След

1 Kaipainen A, VLAYKOVA T, Hatva E, Bohling 179 – от тях- 76 в списания с T, Jekunen A, Pyrhonen S, Alitalo K. Enhanced ИФ, 9 в дисертации в чужбина Expression of the TIE Receptor Tyrosine Kinase и 3 в монографии в чужбина Messenger-RNA in the Vascular Endothelium of Metastatic Melanomas. CANCER RESEARCH + в 91 патента 1994; 54 (24):6571-6577 2 Sauroja I, Smeds J, VLAYKOVA T, Kumar R, 48– от тях -41 списания с ИФ, Talve L, Hahka-Kemppinen M, Punnonen K, 4 в дисертации в чужбина, 1 в Jansen CT, Hemminki K, Pyrhonen S Analysis монографии в чужбина и 2 в of G(1)/S checkpoint regulators in metastatic интернет сайт. melanoma GENES CHROMOSOMES & CANCER 28 (4): 404-414 AUG 2000 3 Gulubova MV, VLAYKOVA T Tenascin 6 в списания с ИФ immunoreactivity in the large bowel and the liver in patients with colorectal cancer HISTOCHEMICAL JOURNAL 33 (2): 111-120 FEB 2001 4 Nikkola J, Vihinen P, VLAYKOVA T, Hahka- 52 – от тях- 45 в списания с Kemppinen M, Kahari VM, Pyrhonen S High ИФ, 6 в дисертации в чужбина expression levels of collagenase-1 and и 1 в патент stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma +6 INTERNATIONAL JOURNAL OF CANCER 97 (4): 432-438 FEB 1 2002 5 VLAYKOVA T, Muhonen T, HahkaKemppinen 25 – от тях- 21 в списания с M, Pyrhonen S, Jekunen A Vascularity and ИФ, 2 в дисертации в prognosis of metastatic melanoma чужбина, 1 в монографии в INTERNATIONAL JOURNAL OF CANCER чужбина и 1 в патент 1997; 74 (3): 326-329 6 Aladjov E, VLAYKOVA T Changes in serum 6 в списания с ИФ ceruloplasmin activity after whole body irradiation of mammals JOURNAL OF RADIATION RESEARCH 38 (3): 157-163 SEP 1997 7 Nikkola J, Vihinen P, Vlaykova T, et al. Integrin 46– от тях- 41 в списания с chains beta 1 and alpha v as prognostic factors in ИФ, 3 в дисертации в human metastatic melanoma Melanoma Res, 14 чужбина, 1 в патент, и 1 в (1): 29-37, 2004 международен проект

8 Nikkola J, Vihinen P, VLAYKOVA T, Hahka- 17– от тях- 12 в списания с +1 2 Kemppinen M, Kahari VM, Pyrhonen S. High ИФ, 4 в дисертации в collagenase-1 expression correlates with a чужбина, 1 в патент favourable chemoimmunotherapy response in human metastatic melanoma MELANOMA RESEARCH 11 (2): 157-166 2001 9 Vihinen P, Nikkola J, VLAYKOVA T, Hahka- 15 – от тях- 11 в списания с Kemppinen M, Talve L, Heino J, Pyrhonen S. ИФ, 2 в дисертации в чужбина Prognostic value of beta 1 integrin expression in и 2 в монографии в чужбина metastatic melanoma MELANOMA RESEARCH 10 (3): 243-251 JUN 2000 10 VLAYKOVA T, Laurila P, Muhonen T, Hahka- 62– от тях- 55 в списания с Kemppinen M, Jekunen A, Alitalo K, Pyrhonen ИФ, 5 в дисертации в S. Prognostic value of tumour vascularity in чужбина, 2 в монографии в metastatic melanoma and association of blood чужбина vessel density with vascular endothelial growth factor expression MELANOMA RESEARCH 1999; 9 (1): 59-68 11 Ilmonen S, Kariniemi AL, VLAYKOVA T, 33 – от тях- 25 в списания с Muhonen T, Pyrhonen S, Asko-Seljavaara S ИФ, 4 в дисертации в Prognostic value of tumour vascularity in чужбина, 4 в монографии в primary melanoma MELANOMA RESEARCH чужбина 9 (3): 273-278 JUN 1999

12 VLAYKOVA T, Jekunen AP, Kesomaa M, 4 – от тях 3 в списания с ИФ,1 Kairemo KJA, Pyrhonen S, Wasenius VM патента Increased thymidylate synthase gene expression in metastatic melanoma ONCOLOGY 54 (2): 146-152 1997 13 VLAYKOVA T, Talve L, Hahka-Kemppinen M, 28 – от тях- 24 в списания с Hernberg M, Muhonen T, Collan Y, Pyrhonen S. ИФ, 3 в дисертации в Immunohistochemically detectable Bcl-2 чужбина, 1 в монографии в expression in metastatic melanoma: Association чужбина with survival and treatment response ONCOLOGY 62 (3): 259-268 2002 14 VLAYKOVA T, Talve L, Hahka-Kemppinen M, 12 – от тях- 8 в списания с ИФ, Hernberg M, Muhonen T, Franssila K, Collan Y, 1 в дисертации в чужбина, 3 в Pyrhonen S MIB-1 immunoreactivity correlates монографии в чужбина with blood vessel density and survival in disseminated malignant melanoma ONCOLOGY 57 (3): 242-252 1999 15 Hristozov D, Gadjeva V, VLAYKOVA T, 53 – от тях- 47 в +1 Dimitrov G. Evaluation of oxidative stress in международни списания, patients with cancer.ARCH PHYSIOL повечето с ИФ, 3 в български BIOCHEM 2001 Oct 109:4 331-6 списания, 2 в дисертации в чужбина, 1 в монографии в чужбина

16 Gadjeva, V., VLAJKOVA, T., Popova, E., et al. 9- 1 в сп. с IF, 8 в български Reactive oxygen species, antioxidant enzymes списания and human diseases. Review- I. BULGARIAN MEDICINE 2000.Vol VIII, N5 pp.21-24 3

17 Kuchukova D, Gadjeva V, VLAYKOVA T, 2 в български списания Ivanova V, Georgieva R. Influence of chemotherapy on the antioxidant status in patients with various hematological diseases, IMAB Annual proceedings (Scientific papers), 2001; 7(1):111-113 18 Gulubova M, VLAYKOVA T. 10 – от тях -10 в списания с Immunohistochemical assessment of fibronectin ИФ, 2 в интернет сайт. and tenascin and their integrin receptors alpha5beta1 and alpha9beta1 in gastric and colorectal cancers with lymph node and liver metastases, Acta Histochem. 2006;108(1):25- 35(IF=0,656) 19 Vodenicharov A, Leiser R, Gulubova M, 7 – от тях- 6 в списания с ИФ, VLAYKOVA T. Morphological and 1 в дисертации в чужбина Immunocytochemical Investigations on Mast Cells in Porcine Ureter. Anat Histol Embryol. 2005;34(6):343-349. (IF-=0,372, 2005) 20 VLAYKOVA T, Miteva L, Gulubova M, 11 – от тях- 9в международни Stanilova S. Ile105Val GSTP1 polymorphism and списания, 1 в български susceptibility to colorectal carcinoma in списания, 1 в дисертации в Bulgarian population Int J Colorectal Dis. 2007, България 22(10), 1209-1215 (IF=1,646, 2007) 21 Gulubova M.V., Manolova I.M., VLAYKOVA 6в списания с ИФ T.I., Prodanova M., Jovchev J.P. Adhesion molecules in chronic ulcerative colitis (2007) International Journal of Colorectal Disease, 22 (6), pp. 581-589. 22 Djouvinov, D., S. Boicheva, T. Simeonova and 4 – от тях- 3 в списания с ИФ, T. VLAIKOVA 2005. Effect of feeding 1 в дисертации в чужбина Lactina® probiotic on performance, some blood parameters and caecal microflora of mule ducklings. Trakia J. Sci., 3: 22-28. 23 Gulubova M., VLAYKOVA T. Prognostic 12 в списания с ИФ significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer (2007) J Gastroenterol Hepatol, 24 Vuoristo M, Vihinen P, VLAYKOVA T, 7- 6 в списания с ИФ, 1 в Nylund C, Heino J, Pyrhonen S. Increased gene патент expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma. Melanoma Res. 2007, 17(4):215-223. (IF=1,534, 2005) 25 Sarov GM, Ilieva GS, VLAYKOVA TI, (2004) 4-1 в дисертации в България A case with unusual blood chemistry parameters +3 Бг списания following a glucose tolerance test and stress. Bulg J Vet Medicine 7(4): 235-238, 2004 26 Sarov G.M. & VLAYKOVA T.I. 2005. Changes 1 в списания в чужбина in blood glucose, triglycerides and lipid 4 peroxidation products in rabbits after hanging fixation. Bulgarian Journal of Veterinary Medicine. 8: 157-590. 27 Gulubova MV, VLAYKOVA TI Significance of 3 в списания в чужбина tenascin-C, fibronectin, laminin, collagen IV, alpha 5 beta 1 and alpha 9 beta 1 integrins and fibrotic capsule formation around liver metastases originating from cancers of the digestive tract. NEOPLASMA Volume: 53 Issue: 5 Pages: 372-383 Published: 2006 28. Gulubova MV, Vlaykova TI. Mast cells in 1 дисертация в чужбина human bile duct obstruction. J Mol Histol. 35: 791-801. 2004 29 Gulubova M.V., Yovchev Y., Vlaykova T., 1 в списания с ИФ Hadjipetkov P., Prangova D.K., Popharitov A. Application of light microscopical and ultrastructural immunohistochemistry in the study of goblet cell carcinoid in the appendix (2008) World Journal of Surgical Oncology, 6, art. no. 15

30 Gulubova M, Vlaykova T, Manolova I, 1 в списания с ИФ Hadjipetkov P, Popharitov A. Implication of adhesion molecules in inflammation of the common bile duct in patients with secondary cholangitis due to biliary obstruction. Hepatogastroenterology. 2008 May- Jun;55(84):836-41. 31 Djouvinov D, Stefanov M, Boicheva S, Vlaikova 4 международни T. Effect of diet formulation on basis of digestive amino acids and supplementation of probiotic on performance of broiler chicks. Trakia J Sci, 2005; 3 (1):61-69 ОБЩО: 669

5 1. Цитирана статия:

ENHANCED EXPRESSION OF THE TIE RECEPTOR TYROSINE KINASE MESSENGER- RNA IN THE VASCULAR ENDOTHELIUM OF METASTATIC MELANOMAS KAIPAINEN A, VLAYKOVA T, HATVA E, et al. CANCER RESEARCH 54 (24): 6571-6577 DEC 15 1994

1. Stevens, M.E., Dhillon, J., Miller, C.A., Messier-Solek, C., Majeske, A.J., Zuelke, D., Rast, J.P., Smith, L.C. SpTie1/2 is expressed in coelomocytes, axial organ and embryos of the sea urchin Strongylocentrotus purpuratus, and is an orthologue of vertebrate Tie1 and Tie2 Developmental and Comparative Immunology, 34 (8) pp. 884-895. 2010

2. Dong, Z., Nör, J.E. Transcriptional targeting of tumor endothelial cells for gene therapy. Advanced Drug Delivery Reviews, 61 (7-8) pp. 542-553., 2009

3. Su, D; Gudas, LJ Retinoic acid receptor gamma activates receptor tyrosine kinase Tie1 gene transcription through transcription factor GATA4 in F9 stem cells. EXPERIMENTAL HEMATOLOGY 36 (5): 624-641 MAY 2008

4. Haluska, F; Pemberton, T; Ibrahim, N; Kalinsky, K. The RTK/RAS/BRAF/PI3K pathways in melanoma: Biology, small molecule inhibitors, and potential applications. SEMINARS IN ONCOLOGY 34 (6): 546-554 DEC 2007.

5. Hewett PW, Daft EL, Laughton CA, et al. Selective inhibition of the human Tie-1 promoter with triplex-forming oligonucleotides targeted to Ets binding sites MOLECULAR MEDICINE 12 (1- 3): 8-16 JAN-MAR 2006 6. Streit S, Mestel DS, Schmidt M, et al.FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients BRITISH JOURNAL OF CANCER 94 (12): 1879-1886 JUN 19 2006 7. Kato S, Shimoda H, Ji RC, et al.Lymphangiogenesis and expression of specific molecules as lymphatic endothelial cell markers ANATOMICAL SCIENCE INTERNATIONAL 81 (2): 71-83 JUN 2006 8. Ramage JM, Spendlove I, Rees R, et al.The use of reverse immunology to identify HLA-A2 binding epitopes in Tie-2 CANCER IMMUNOLOGY IMMUNOTHERAPY 55 (8): 1004-1010 AUG 2006 9. Huang XL, Brown C, Ni WH, et al.Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis BLOOD 107 (8): 3153-3160 APR 15 2006 10. Steukers M, Schaus JM, van Gool R, et al.Rapid kinetic-based screening of human Fab fragments JOURNAL OF IMMUNOLOGICAL METHODS 310 (1-2): 126-135 MAR 20 2006

11. Saharinen P, Kerkela K, Ekman N, et al.Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2 JOURNAL OF CELL BIOLOGY 169 (2): 239-243 APR 25 2005 12. Jeong CH, Lee YM, Choi KS, et al.Hypoxia-responsive element-mediated soluble Tie2 vector exhibits an anti-angiogenic activity in vitro under hypoxic condition INTERNATIONAL JOURNAL OF ONCOLOGY 26 (1): 211-216 JAN 2005

6 13. Chin KF, Greenman J, Reusch P, et al.Changes in serum soluble VEGFR-1 and Tie-2 receptors in colorectal cancer patients following surgical resections ANTICANCER RESEARCH 24 (4): 2353-2357 JUL-AUG 2004 14. Jostock T, Vanhove M, Brepoels E, et al.Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries JOURNAL OF IMMUNOLOGICAL METHODS 289 (1-2): 65-80 JUN 2004 15. Ramage JM, Metheringham R, Conn A, et al.Identification of an HLA-A*0201 cytotoxic T lymphocyte epitope specific to the endothelial antigen Tie-2 INTERNATIONAL JOURNAL OF CANCER 110 (2): 245-250 JUN 10 2004 16. Dales JP, Garcia S, Carpentier S, et al.Prediction of metastasis risk (11 year follow-up) using VEGF-R1, VEGF-R2, Tie-2/Tek and CD105 expression in breast cancer (n=905) BRITISH JOURNAL OF CANCER 90 (6): 1216-1221 MAR 22 2004 17. Ito Y, Yoshida H, Uruno T, et al.Tie-1 tyrosine kinase expression in human thyroid neoplasms HISTOPATHOLOGY 44 (4): 318-322 APR 2004 18. Dales JP, Garcia S, Carpentier S, et al.Long-term prognostic significance of neoangiogenesis in breast carcinomas: Comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression HUMAN PATHOLOGY 35 (2): 176-183 FEB 2004

19. Karnani P, Kairemo K Targeting endothelial growth with monoclonal antibodies against Tie-1 kinase in mouse models CLINICAL CANCER RESEARCH 9 (10): 3821S-3826S Part 2 Suppl. 2 SEP 1 2003 20. Feraud O, Mallet C, Vilgrain IExpressional regulation of the angiopoietin-1 and-2 and the endothelial-specific receptor tyrosine kinase tie2 in adrenal atrophy: A study of adrenocorticotropin-induced repair ENDOCRINOLOGY 144 (10): 4607-4615 OCT 1 2003 21. Chin KF, Greenman J, Reusch P, et al.Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 29 (6): 497-505 AUG 2003 22. Fisher MJ, Adamson PCAnti-angiogenic agents for the treatment of brain tumors NEUROIMAGING CLINICS OF NORTH AMERICA 12 (4): 477+ NOV 2002 23. Dales JP, Garcia S, Bonnier P, et al.Tie2/Tek expression in breast car cinoma: Correlations of immunohistochemical assays and long-term follow-up in a series of 909 patients INTERNATIONAL JOURNAL OF ONCOLOGY 22 (2): 391-397 FEB 2003 24. Iljin K, Petrova TV, Veikkola T, et al.A fluorescent Tie1 reporter allows monitoring of vascular development and endothelial cell isolation from transgenic mouse embryos FASEB JOURNAL 16 (13): 1764-1774 NOV 2002 25. Gaspar J, Thai S, Voland C, et al.Opposing functions of the Ets factors NERF and ELF-1 during chicken blood vessel development ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 22 (7): 1106-1112 JUL 2002 26. Ward NL, Dumont DJThe angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY 13 (1): 19-27 FEB 2002 27. Christensen RA, Fujikawa K, Madore R, et al.NERF2, a member of the ets family of transcription factors, is increased in response to hypoxia and angiopoietin-1: A potential mechanism for Tie2 regulation during hypoxia JOURNAL OF CELLULAR BIOCHEMISTRY 85 (3): 505-515 2002 28. Dhar DK, Naora H, Yamanoi A, et al.Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: A comparison with angiopoietin/Tie pathway ANTICANCER RESEARCH 22 (1A): 379-386 JAN-FEB 2002 29. Maulik N, Das DKPotentiation of angiogenic response by ischemic and hypoxic preconditioning of the heart JOURNAL OF CELLULAR AND MOLECULAR MEDICINE 6 (1): 13-24 JAN-MAR 2002 7 30. Kontos CD, Cha EH, York JD, et al.The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis MOLECULAR AND CELLULAR BIOLOGY 22 (6): 1704-1713 MAR 2002 31. Scott BB, Zaratin PF, Colombo A, et al.Constitutive expression of angiopoietin-1 and-2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts JOURNAL OF RHEUMATOLOGY 29 (2): 230-239 FEB 2002 Times Cited: 26 32. Tseng LM, Hsu CY, Wang HC, et al.Tie-1 tyrosine kinase is an independent prognostic indicator for invasive breast cancer ANTICANCER RESEARCH 21 (3C): 2163-2170 MAY- JUN 2001 33. Jones N, Iljin K, Dumont DJ, et al.Tie receptors: New modulators of angiogenic and lymphangiogenic responses NATURE REVIEWS MOLECULAR CELL BIOLOGY 2 (4): 257- 267 APR 2001 34. Kampfer H, Pfeilschifter J, Frank S Expressional regulation of angiopoietin-1 and-2 and the tie-1 and-2 receptor tyrosine kinases during cutaneous wound healing: A comparative study of normal and impaired repair LABORATORY INVESTIGATION 81 (3): 361-373 MAR 2001 35. Nguyen LL, D'Amore PACellular interactions in vascular growth and differentiation INTERNATIONAL REVIEW OF CYTOLOGY-A SURVEY OF CELL BIOLOGY 204: 1-48 2001 36. Webb CP, Woude GFVGenes that regulate metastasis and angiogenesis JOURNAL OF NEURO-ONCOLOGY 50 (1-2): 71-87 OCT 2000 37. Reijneveld JC, Voest EE, Taphoorn MJBAngiogenesis in malignant primary and metastatic brain tumors JOURNAL OF NEUROLOGY 247 (8): 597-608 AUG 2000 38. Thorpe PE, Ran STumor infarction by targeting tissue factor to tumor vasculature CANCER JOURNAL 6: S237-S244 Suppl. 3 MAY 2000 39. Cherrington JM, Strawn LM, Shawver LKNew paradigms for the treatment of cancer: The role of anti-angiogenesis agents ADVANCES IN CANCER RESEARCH 79: 1-38 2000 40. Beckner ME Factors promoting tumor angiogenesis CANCER INVESTIGATION 17 (8): 594-623 1999 41. Lin EY, Piepkorn M, Garcia R, et al.Angiogenesis and vascular growth factor receptor expression in malignant melanoma PLASTIC AND RECONSTRUCTIVE SURGERY 104 (6): 1666-1674 NOV 1999 42. Zagzag D, Hooper A, Friedlander DR, et al.In situ expression of angiopoietins in astrocytomas identifies angiopoietin-2 as an early marker of tumor angiogenesis EXPERIMENTAL NEUROLOGY 159 (2): 391-400 OCT 43. Bloemendal HJ, Logtenberg T, Voest EE New strategies in anti-vascular cancer therapy EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 29 (9): 802-809 SEP 1999 44. Takahama M, Tsutsumi M, Tsujiuchi T, et al.Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas CLINICAL CANCER RESEARCH 5 (9): 2506-2510 SEP 1999 45. Fujikawa K, Presman E, Isner JM, et al.Expression of Tie1 and Tie2 proteins during reendothelialization in balloon-injured rat carotid artery JOURNAL OF VASCULAR RESEARCH 36 (4): 272-281 JUL-AUG 1999 46. Otani A, Takagi H, Oh H, et al.Expressions of angiopoietins and Tie2 in human choroidal neovascular membranes INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 40 (9): 1912-1920 AUG 1999 47. Lin WC, Li AFY, Chi CW, et al. tie-1 protein tyrosine kinase: A novel independent prognostic marker for gastric cancer CLINICAL CANCER RESEARCH 5 (7): 1745-1751 JUL 1999 48. McCarthy MJ, Burrows R, Bell SC, et al.Potential roles of metalloprotease mediated ectodomain cleavage in signaling by the endothelial receptor tyrosine kinase Tie- 1 LABORATORY INVESTIGATION 79 (7): 889-895 JUL 1999 8 49. Siemeister G, Schirner M, Weindel K, et al.Two independent mechanisms essential for tumor angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway CANCER RESEARCH 59 (13): 3185-3191 JUL 1 1999 50. Dube A, Akbarali Y, Sato TN, et al.Role of the Ets transcription factors in the regulation of the vascular-specific Tie2 gene CIRCULATION RESEARCH 84 (10): 1177-1185 MAY 28 1999 51. Takahashi A, Sasaki H, Kim SJ, et al.Identification of receptor genes in renal cell carcinoma associated with angiogenesis by differential hybridization technique BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 257 (3): 855-859 APR 21 1999 52. Yabkowitz R, Meyer S, Black T, et al.Inflammatory cytokines and vascular endothelial growth factor stimulate the release of soluble tie receptor from human endothelial cells via metalloprotease activation BLOOD 93 (6): 1969-1979 MAR 15 1999 53. Iljin K, Dube A, Kontusaari S, et al.Role of Ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter FASEB JOURNAL 13 (2): 377-386 FEB 1999 54. Partanen J, Dumont DJFunctions of Tie1 and Tie2 receptor tyrosine kinases in vascular development CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY 237: 159, 1999 55. Lauren J, Gunji YJ, Alitalo KIs angiopoietin-2 necessary for the initiation of tumor angiogenesis? AMERICAN JOURNAL OF PATHOLOGY 153 (5): 1333-1339 NOV 1998 56. Stratmann A, Risau W, Plate KHCell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis AMERICAN JOURNAL OF PATHOLOGY 153 (5): 1459-1466 NOV 1998 57. Witzenbichler B, Maisonpierre PC, Jones P, et al.Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2 JOURNAL OF BIOLOGICAL CHEMISTRY 273 (29): 18514-18521 JUL 17 1998 58. Chaplin DJ, Hill SA, Bell KM, et al.Modification of tumor blood flow: Current status and future directions SEMINARS IN RADIATION ONCOLOGY 8 (3): 151-163 JUL 1998 59. Brattstrom D, Bergqvist M, Larsson A, et al.Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients ANTICANCER RESEARCH 18 (2A): 1123-1127 MAR-APR 1998 60. Peters KG, Coogan A, Berry D, et al.Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis BRITISH JOURNAL OF CANCER 77 (1): 51-56 JAN 1998 61. Kolibaba KS, Druker BJProtein tyrosine kinases and cancer BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER 1333 (3): F217-F248 DEC 9 1997 62. Kin M, Sata M, Ueno A, et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism JOURNAL OF HEPATOLOGY 27 (4): 677-687 OCT 1997 63. Thorpe PE, Derbyshire EJTargeting the vasculature of solid tumours JOURNAL OF CONTROLLED RELEASE 48 (2-3): 277-288 OCT 13 1997 64. Yabkowitz R, Meyer S, Yanagihara D, et al.Regulation of tie receptor expression on human endothelial cells by protein kinase C-mediated release of soluble tie BLOOD 90 (2): 706-715 JUL 15 65. Wernert NThe multiple roles of tumour stroma VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY 430 (6): 433-443 JUN 1997 66. Chen QY, Seol DW, Carr B, et al.Co-expression and regulation of Met and Ron proto- oncogenes in human hepatocellular carcinoma tissues and cell lines HEPATOLOGY 26 (1): 59- 66 JUL 1997 67. Shawver LK, Lipson KE, Fong TAT, et al.Receptor tyrosine kinases as targets for inhibition of angiogenesis DRUG DISCOVERY TODAY 2 (2): 50-63 FEB 1997 9 68. Merenmies J, Parada LF, Henkemeyer MReceptor tyrosine kinase signaling in vascular development CELL GROWTH & DIFFERENTIATION 8 (1): 3-10 JAN 1997 69. Davis S, Aldrich TH, Jones PF, et al.Isolation of Angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning CELL 87 (7): 1161-1169 DEC 27 1996 70. Salven P, Joensuu H, Heikkila P, et al.Endothelial Tie growth factor receptor provides antigenic marker for assessment of breast cancer angiogenesis BRITISH JOURNAL OF CANCER 74 (1): 69-72 JUL 1996 71. Sliutz G, Tempfer C, Obermair A, et al.Serum evaluation of basic FGF in breast cancer patients ANTICANCER RESEARCH 15 (6B): 2675-2677 NOV-DEC 1995 72. Paavonen K, HorelliKuitunen N, Chilov D, et al.Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively CIRCULATION 93 (6): 1079-1082 MAR 15 1996 73. Plate KH, Risau W Angiogenesis in malignant gliomas GLIA 15 (3): 339-347 NOV 1995 74. Korhonen J, Lahtinen I, Halmekyto M, et al.Endothelial-specific gene-expression directed by the tie gene promoter in-vivo BLOOD 86 (5): 1828-1835 SEP 1 1995 75. Sliutz G, Tempfer C, Obermair A, et al.Serum evaluation of basic fibroblast growth-factor in cervical-cancer patients CANCER LETTERS 94 (2): 227-231 AUG 1 1995 76. Laurie M Strawn, Laura K Shawver Tyrosine kinases in disease: overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials. Expert Opinion on Investigational Drugs April 1998, Vol. 7, No. 4, Pages 553-573

PhD theses

77. Piia Vuorela. Vascular endothelial groth factor, its receptors, and the Tie receptor in normal and complicated pregnancy. PhD thesis book; Helsinki University, 2000 Dept. Obstetrics and Gynaecology, Helsinki University Central Hospital, University of Helsinki 78. Athina Lymboussaki. Vascular endothelial groth factors and their receptors in embryos, adults and in tumors. PhD thesis book; Helsinki University, 1999 Molecular/Cancer Biology Laboratory and Dept. Of Pathology, Haartman Institute and Dept. Of Biosciences, Devision of Genetics 79. Graells Estrada, Jordi, Angiogиnesi al Melanoma Maligne. Anаlisi de l’efecte de l’estimulaciу amb Matrigel, de la relaciу amb l’expressiу del Factor de Creixement de l’Endoteli Vascular (VEGF) i de l’efecte de la transfecciу del cDNA del VEGF en sentit i antisentit sobre l’angiogиnesi i el comportament tumorals. Estudi en melanomes humans i en lнnies de melanoma humа xenoempeltades a ratolins immunodeprimits. . PhD thesis book; 2004, Spain (http://www.tesisenxarxa.net/TESIS_UB/AVAILABLE/TDX-0414105-093745/) 80. Erden Radoncic, PhD Thesis, Cimbenik rasta vaskularnog endotela i posteljicni cimbenik rasta u serumu i folikulinskoj tekucini pacijentica podvrgnutih izvantjelesnoj oplodnji, Zagreb, 2006 81. Lyuba Varticovski, PhD Thesis: Role of Angiogenic Growth Factor Receptors, Tie 1 and Tie 2, in Metastatic Potential of Breast Cancer, BOSTON MA, 1999 http://www.stormingmedia.us/10/1072/A107283.html 82. Petra Bisplinghoff, PhD Thesis: Angiogenese, Anti-Angiogenese und vaskuläre Regression am Modell des bovinen Corpus luteum, Berlin 2006 http://www.diss.fu- berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000002514/ http://www.diss.fu- berlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000002514/11_litv.pdf?host s= 83. Mira Connna Puri – PhD Thesis- The role of TEK and TIE receptor tyrosine kinases in murine cardiovascular development The authorretauis ownership of the copyright in this thesis. Neitherthe thesis nor substantial extracts fkom it may be printed or otheMrise reproduced without the author's permission. 10 [https://tspace.library.utoronto.ca/bitstream/1807/12944/1/NQ41280.pdf], University of Toronto, 1999 84. Sema Sandra Sevinc, PhD Thesis, Strukturelle Stabilisierung der Tumorblutgefäße und ihre Auswirkung beim Tumorwachstum am Beispiel vom Rhabdomyosarkom der Ratte. Univ., Diss., 2006--Hamburg [http://www.sub.uni- hamburg.de/opus/volltexte/2007/3248/pdf/Promotion_2007.pdf 85. Dominik Sebastian Mestel- PhD - Proteinexpression und Genpolymorphismus des Fibroblasten-Wachstumsfaktor- Rezeptors-4 (FGFR4) bei Patienten mit malignen Melanomen, München, 2008

86. In BOOK: Endothelial Biomedicine, Edd. William C. Aird, p 1468, Cambridge University Press, 2007. http://books.google.bg/books?id=16_Xy2CXaxcC&pg=PA1468&lpg=PA1468&dq=Vlaykova+ T&source=web&ots=t79fOg5wnP&sig=6GWAB9c6foJ4ck3U3QSr5OhYd2s&hl=bg&sa=X&o i=book_result&resnum=10&ct=result 87. Chien-Fu Hung, Archana Monie and T. -C. Wu , Book Chapter 39: Immunotherapy of Angiogenesis with DNA Vaccines, In: Angiogenesis An Integrative Approach From Science to Medicine, Edds. William D. Figg and Judah Folkman, Springer US, 2008, 451-460 88. In BOOK: The Basic Science of Oncology, Ian Tannock, Richard P. Hill, Robert G. Bristow, Lea Harrington, Fourth Eddition, p246, , McGraw-Hill Professional, 2005 http://books.google.bg/books?id=Bb4F4pj2BdYC&pg=PA246&lpg=PA246&dq=Vlaykova +T&source=web&ots=bD0W2nmbnL&sig=UjJjjo4hP6i98j5r2Du3ND43PTw&hl=bg&sa= X&oi=book_result&resnum=7&ct=result

2. Цитирана статия: Analysis of G(1)/S checkpoint regulators in metastatic melanoma SAUROJA I, SMEDS J, VLAYKOVA T, et al. GENES CHROMOSOMES & CANCER 28 (4): 404-414 AUG 2000

1. Karim, R.Z., Gerega, S.K., Yang, Y.H., Spillane, A., Carmalt, H., Scolyer, R.A., Lee, C.S. P16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes. Histopathology, 56 (7) pp. 868-875. 2010

2. Rothberg, BEG; Berger, AJ; Molinaro, AM; Subtil, A; Krauthammer, MO; Camp, RL; Bradley, WR; Ariyan, S; Kluger, HM; Rimm, DL. Melanoma Prognostic Model Using Tissue Microarrays and Genetic Algorithms. JOURNAL OF CLINICAL ONCOLOGY 27 (34): 5772- 5780 DEC 1 2009. 3. Chen, JY; Etzel, CJ; Amos, CI; Zhang, Q; Viscofsky, N; Lindor, NM; Lynch, PM; Frazier, ML. Genetic variants in the cell cycle control pathways contribute to early onset colorectal cancer in Lynch syndrome. CANCER CAUSES & CONTROL 20 (9): 1769-1777 NOV 2009. 4. Karim, RZ; Li, W; Sanki, A; Colman, MH; Yang, YH; Thompson, JF; Scolyer, RA. Reduced p16 and Increased Cyclin D1 and pRb Expression Are Correlated With Progression in Cutaneous Melanocytic Tumors. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY 17 (5): 361-367 OCT 2009. 5. Rothberg, BEG; Bracken, MB; Rimm, DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. JOURNAL OF THE NATIONAL CANCER INSTITUTE 101 (7): 452-474 APR 1 2009 11 6. Chen, JY; Li, DH; Killary, AM; Sen, S; Amos, CI; Evans, DB; Abbruzzese, JL; Frazier, ML. Polymorphisms of p16, p27, p73, and MDM2 Modulate Response and Survival of Pancreatic Cancer Patients Treated with Preoperative Chemoradiation. ANNALS OF SURGICAL ONCOLOGY 16 (2): 431-439 FEB 2009

7. Box, NF; Terzian, T. The role of p53 in pigmentation, tanning and melanoma. PIGMENT CELL & MELANOMA RESEARCH 21 (5): 525-533 OCT 2008 8. Kwinta, L. The role of non-coding sequences in melanoma carcinogenesis. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY 12 (3): 99-106 MAY 2008. 9. Yan, L; Na, W; Shan, K; Xiao-Wei, M; Wei, G; Shu-Cheng, C. p16(CDKN2) gene polymorphism: association with histologic subtypes of epithelial ovarian cancer in China. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 18 (1): 30-35 JAN-FEB 2008 10. Jasmine Healy, Helene Belanger, Patrick Beaulieu, Mathieu Lariviere, Damian Labuda, and Daniel Sinnett, Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia, 2008 05 23 21:38:35 Friday , 19 11. WANG Na LI Yan DONG Xiu-juan GUO Wei WANG Shi-jie Association between p16 Gene C540G and C580T Polymorphisms and Esophageal Squamous Cell Carcinoma and Gastric Cardiac Adenocarcinoma. CANCER RESEARCH ON PREVENTION AND TREATMENT. 2008 35(1) R735.1 R735.2 (http://d.wanfangdata.com.cn/Periodical_zlfzyj200801018.aspx)

12. Dres. Alejandra Larre Borges García*, Malena Scarone†, Lucía Delgado‡, Jimena Núñez§, Mercedes Laporte¶, Graciela Fernández††, Carlos Bazzano‡‡, Miguel Martínez Asuaga§ Predisposición hereditaria de padecer melanoma en familias uruguayas. Resultados preliminares. Rev Med Urug 2007; 23: 109-115 13. Lamperska, KM; Przybyla, A; Kycler, W; Mackiewicz, A. The CDAKN2a common variants: 148 Ala/Thr and 500 C/G in 3 ' UTR, and their association with clinical course of melanoma. ACTA BIOCHIMICA POLONICA 54 (1): 119-124 2007. 14. Chen, JY; Li, DH; Wei, CJ; Sen, S; Killary, AM; Amos, CI; Evans, DB; Abbruzzese, JL; Frazier, ML Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. CLINICAL CANCER RESEARCH 13 (10): 3100-3104 MAY 15 2007 15. Healy, J; Belanger, H; Beaulieu, P; Lariviere, M; Labuda, D; Sinnett, D, Promoter SNPs in G(1)/S checkpoint regulators and their impact on the susceptibility to childhood leukemia, BLOOD 109 (2): 683-692 JAN 15 2007

16. Li W, Sanki A, Karim RZ, et al.The role of cell cycle regulatory proteins in the pathogenesis of melanoma PATHOLOGY 38 (4): 287-301 AUG 2006

17. McDonald R, Scott Winters R, Ankuda CK, Murphy JA, Rogers AE, Pereira F, Greenblatt MS, White PS. An automated procedure to identify biomedical articles that contain cancer- associated gene variants. Hum Mutat. 2006 Sep;27(9):957-64. 18. Carlson JA, Ross J, Murphy MMarkers of high-risk cutaneous melanoma: is there a winning combination for individualized prognosis? JOURNAL OF CUTANEOUS PATHOLOGY 32 (10): 700-703 NOV 2005 19. Geddert H, Kiel S, Zotz RB, et al.Polymorphism of p16(INK4A) and cyclin D1 in adenocarcinomas of the upper gastrointestinal tract JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY 131 (12): 803-808 DEC 2005 20. Soto JL, Cabrera CM, Serrano S, et al.Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B BMC CANCER, Volume 5, 8 April 2005, Article number 36, 9p 12 21. Soto Martínez JL, Cabrera Morales CM, Serrano Ortega S, López-Nevot MÁ. Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15. Clin Transl Oncol. 2005;7(4):156-64. 22. Berger AJ, Camp RL, DiVito KA, et al.Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome CANCER RESEARCH 64 (23): 8767-8772 DEC 1 2004 23. Woenckhaus C, Fenic I, Giebel J, et al.Loss of heterozygosity at 12p13 and loss of p27KIP1 protein expression contribute to melanoma progression VIRCHOWS ARCHIV 445 (5): 491- 497 NOV 2004 24. Li Q, Murphy M, Ross J, et al.Skp2 and p27(kip1) expression in melanocytic nevi and melanoma: an inverse relationship JOURNAL OF CUTANEOUS PATHOLOGY 31 (10): 633- 642 NOV 2004 25. McCloud JM, Sivakumar R, Greenhough A, et al.p16(INK4a) polymorphism: Associations with tumour progression in patients with sporadic colorectal cancer INTERNATIONAL JOURNAL OF ONCOLOGY 25 (5): 1447-1452 NOV 2004 26. Rodolfo M, Daniotti M, Vallacchi V Genetic progression of metastatic melanoma CANCER LETTERS 214 (2): 133-147 OCT 28 2004 27. Murphy M, Carlson JA, Keough MP, et al.Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27(Kip1) JOURNAL OF CUTANEOUS PATHOLOGY 31 (7): 477-482 AUG 2004 28. Hench LL, Xynos ID, Polak JM Bioactive glasses for in situ tissue regeneration JOURNAL OF BIOMATERIALS SCIENCE-POLYMER EDITION 15 (4): 543-562 2004 29. Loktionov A Common gene polymorphisms, cancer progression and prognosis CANCER LETTERS 208 (1): 1-33 MAY 10 2004 30. Ghiorzo P, Villaggio B, Sementa AR, et al.Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients HUMAN PATHOLOGY 35 (1): 25-33 JAN, 2004 31. Alonso SR, Ortiz P, Pollan M, et al.Progression in cutaneous malignant melanoma is associated with distinct expression profiles - A tissue microarray-based study AMERICAN JOURNAL OF PATHOLOGY 164 (1): 193-203 JAN 2004 32. Perrone F, Tabano S, Colombo F, et al.p15(INK4b), p14(ARF), and p16(INK4a) inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors CLINICAL CANCER RESEARCH 9 (11): 4132-4138 SEP 15 2003 33. Chiorzo, P., Scarrà, G.B. Genetics of melanoma susceptibility. FORUM - Trends in Experimental and Clinical Medicine 13 (2), pp. 114-126, 2003. 34. Hayward NK Genetics of melanoma predisposition ONCOGENE 22 (20): 3053-3062 MAY 19 2003 35. Sakano S, Berggren P, Kumar R, et al.Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene INTERNATIONAL JOURNAL OF CANCER 104 (1): 98-103 MAR 10 2003 36. Zheng YX, Shen HB, Sturgis EM, et al. Haplotype of two variants in p16 (CDKN2/MTS- 1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: a case-control study - Reply CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 12 (1): 72-72 JAN 2003 37. Czajkowski R, Drewa T, Wozniak A, et al.Cell cycle in sporadic melanoma INTERNATIONAL JOURNAL OF DERMATOLOGY 41 (9): 550-556 SEP 2002 38. Hench LL, Xynos ID, Edgar AJ, et al.Gene activating glasses JOURNAL OF INORGANIC MATERIALS 17 (5): 897-909 SEP 2002 39. Zheng YX, Shen HB, Sturgis EM, et al.Haplotypes of two variants in p16 (CDKN2/MTS- 1/INK4a) exon 3 and risk of squamous cell carcinoma of the head and neck: A case-control study CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 11 (7): 640-645 JUL 2002 13 40. Polsky D, Bastian BC, Hazan C, et al.HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma CANCER RESEARCH 61 (20): 7642-7646 OCT 15 2001 41. Xynos ID, Edgar AJ, Buttery LDK, et al.Gene-expression profiling of human osteoblasts following treatment with the ionic products of Bioglass (R) 45S5 dissolution JOURNAL OF BIOMEDICAL MATERIALS RESEARCH 55 (2): 151-157 MAY 2001

PhD Theses

42. Oddbjorn Straume Integrins Biological and Prognostic Markers in Cutaneous Malignant Melanoma, PhD thesis book, University of Bergen, 2002 Dept. Pathology, The Gade Institute, University of Bergen, Norwegian Cancer Societ 43. Sara Tartaglia NEUROFIBROMATOSI DI TIPO 1 E GENI MODIFICATORI PREDISPONENTI L’INSORGENZA DI TUMORI (GLIOMA DELLE VIE OTTICHE) PhD thesis book, UNIVERSITA' DEGLI STUDI DI PADOVA, Italy, 2009 (Tartaglia, Sara (2009) NEUROFIBROMATOSI DI TIPO 1 E GENI MODIFICATORI PREDISPONENTI L’INSORGENZA DI TUMORI (GLIOMA DELLE VIE OTTICHE). [Tesi di dottorato]) http://paduaresearch.cab.unipd.it/1348/1/tesi.pdf 44. Irmela Ulrike Weishaar, Promotormethylierung und Expression der Tumorsuppressorgene p14ARF und p16INK4a in Aderhautmelanomen, PhD thesis book, 2006, Institut fur Pathologie der Universitat Leipzig, Germany, http://www.uniklinikum-leipzig.de/forschung/download/dissertationen/weishaar_2006.pdf 45. Ines Breibach, Molekulare Mechanismen der Regulation von Matrixkontakten und Migration melanozyt¨arer Zellen durch das Protein MIA. PhD thesis book, 2003, Rheinisch- Westf¨alischen Technischen Hochschule, Aachen, Germany (http://darwin.bth.rwth- aachen.de/opus3/volltexte/2003/511/pdf/Breibach_Ines.pdf)

Книги 46. In BOOK: The Pigmentary System, Second Eddition, Edds. James J. Nordlund, Raymond E. Boissy, Vincent J. Hearing, William Oetting, Richard King, Jean-Paul Ortonne, p487, Wiley- Blackwell, 2006 http://books.google.bg/books?id=CtdwxA4NtnQC&pg=PA487&lpg=PA487&dq=Vlaykova+T &source=web&ots=AdL0PgDLT0&sig=5FWk2MSUGE26XVOSUjiaQQsVARM&hl=bg&sa= X&oi=book_result&resnum=4&ct=result

Web sites

47. Welcome to the COSMIC database and website. Reference information for CDKN2A http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=reference&ln=CDKN2A 48. Faienza, M.F. et al., Nishida, N. et al., Miki, K. et al., Scarisbrick, J.J. et al., Dong, Y. et al., et al. MeSH Review, Genes, p16 http://www.wikigenes.org/e/mesh/e/18402.html

3. Цитирана статия Tenascin immunoreactivity in the large bowel and the liver in patients with colorectal cancer GULUBOVA MV, VLAYKOVA T HISTOCHEMICAL JOURNAL 33 (2): 111-120 FEB 2001 14 1. Grodecka, J., Kobos, J., Zielińska-Kaźmierska, B., Manowska, B. Evaluation of stromal proteins expression - Tenastin and fibronectin - In the cysts and dental derived neoplasms of the facial part of the cranium . Wspolczesna Onkologia, 13 (1) pp. 22-27. 2009

2. Zheng, HC; Tsuneyama, K; Cheng, CM; Takahashi, H; Cui, ZG; Nomoto, K; Murai, Y; Takano, Y, Expression of KAI1 and tenascin, and microvessel density are closely correlated with liver metastasis of gastrointestinal adenocarcinoma, JOURNAL OF CLINICAL PATHOLOGY 60 (1): 50-56 JAN 2007

4. Цитирана статия High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma NIKKOLA J, VIHINEN P, VLAYKOVA T, et al. INTERNATIONAL JOURNAL OF CANCER 97 (4): 432-438 FEB 1 2002

1. Rothberg, BEG; Rimm, DL. Biomarkers: The Useful and the Not So Useful- An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY 130 (8): 1971-1987 AUG 2010 2. Zigrino, P; Kuhn, I; Bauerle, T; Zamek, J; Fox, JW; Neumann, S; Licht, A; Schorpp-Kistner, M; Angel, P; Mauch, C. Stromal Expression of MMP-13 Is Required for Melanoma Invasion and Metastasis. JOURNAL OF INVESTIGATIVE DERMATOLOGY 129 (11): 2686-2693 NOV 2009. 3. Yamazoe, Y., Tsubaki, M., Matsuoka, H., Satou, T., Itoh, T., Kusunoki, T., Kidera, Y., Tanimori, Y., Shoji, K., Nakamura, H., Ogaki, M., Nishiura, S., Nishida, S. Dimethylfumarate inhibits tumor cell invasion and metastasis by suppressing the expression and activities of matrix metalloproteinases in melanoma cells. Cell Biology International, 33 (10) pp. 1087- 1094., 2009 4. Tsuchiya, N; Narita, S; Kumazawa, T; Inoue, T; Ma, ZY; Tsuruta, H; Saito, M; Horikawa, Y; Yuasa, T; Satoh, S; Ogawa, O; Habuchi, T. Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. ONCOLOGY REPORTS 22 (3): 493-499 SEP 2009 5. Hoek, K.S. Melanoma progression, gene expression and DNA microarrays. Giornale Italiano di Dermatologia e Venereologia, 144 (1) pp. 39-49, 2009 6. Bourguet, E; Sapi, J; Emonard, H; Hornebeck, W. Control of Melanoma Invasiveness by Anticollagenolytic Agents: A Reappraisal of an Old Concept. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY 9 (5): 576-597 JUN 2009. 7. Rothberg, BEG; Bracken, MB; Rimm, DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. JOURNAL OF THE NATIONAL CANCER INSTITUTE 101 (7): 452-474 APR 1 2009 8. Yang, Z., Yang, S., Misner, B.J., Chiu, R., Liu, F., Meyskens Jr., F.L. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Molecular Cancer Therapeutics, 7 (12) pp. 3751-3760, 2008 9. Quintanilla-Dieck, MJ; Codriansky, K; Keady, M; Bhawan, J; Runger, TM. Cathepsin K in melanoma invasion. JOURNAL OF INVESTIGATIVE DERMATOLOGY 128 (9): 2281-2288 SEP 2008. 10. Pocza, P; Suli-Vargha, H; Darvas, Z; Falus, A. Locally generated VGVAPG and VAPG elastin- derived peptides amplify melanoma invasion via the galectin-3 receptor. INTERNATIONAL JOURNAL OF CANCER 122 (9): 1972-1980 MAY 1 2008 15 11. Radisky, D.C., Przybylo, J.A. Matrix metalloproteinase-induced fibrosis and malignancy in breast and lung. Proceedings of the American Thoracic Society 5 (3), pp. 316-322, 2008 12. Väisänen, A.H., Kallioinen, M., Turpeenniemi-Hujanen, T. Comparison of the prognostic value of matrix metalloproteinases 2 and 9 in cutaneous melanoma Human Pathology 39 (3), pp. 377-385, 2008 13. Kondratiev, S; Gnepp, DR; Yakirevich, E; Sabo, E; Annino, DJ; Rebeiz, E; Laver, NV. Expression and prognostic role of MMP2, MMP9, MMP13, and MMP14 matrix metalloproteinases in sinonasal and oral malignant melanomas. HUMAN PATHOLOGY 39 (3): 337-343 MAR 2008.

14. Cotignola J, Roy P, Patel A, Ishill N, Shah S, Houghton A, Coit D, Halpern A, Busam K, Berwick M, Orlow I. Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression. Journal of Negative Results in BioMedicine 2007, 6:9 15. Cotignola J, Reva B, Mitra N, Ishill N, Chuai S, Patel A, Shah S, Vanderbeek G, Coit D, Busam K, Halpern A, Houghton A, Sander C, Berwick M, Orlow I. Matrix Metalloproteinase-9 (MMP- 9) polymorphisms in patients with cutaneous malignant melanoma. BMC Medical Genetics 2007, 8:10 16. Iida, J; McCarthy, JB. Expression of collagenase-1 (MMP-1) promotes melanoma growth through the generation of active transforming growth factor-beta. MELANOMA RESEARCH 17 (4): 205-213 AUG 2007 17. Tsareva, SA; Moriggl, R; Corvinus, FM; Wiederanders, B; Schutz, A; Kovacic, B; Friedrich, K. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. NEOPLASIA 9 (4): 279-291 APR 2007. 18. Pearce, EG; Laxton, RC; Pereira, AC; Ye, S. Haplotype effects on matrix metalloproteinase-1 gene promoter activity in cancer cells. MOLECULAR CANCER RESEARCH 5 (3): 221-227 MAR 2007 19. Fukuda K, Fujitsu Y, Kumagai N, et al.Inhibition of matrix metalloproteinase-3 synthesis in human conjunctival fibroblasts by interleukin-4 or interleukin-13 INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 47 (7): 2857-2864 JUL 2006 20. Dedieu S, Lefebvre P, Retinoids interfere with the AP1 signalling pathway in human breast cancer cells CELLULAR SIGNALLING 18 (6): 889-898 JUN 2006 21. Corte MD, Gonzalez LO, Corte MG, et al.Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS 20 (4): 242-248 OCT-DEC 2005 22. Demers M, Couillard J, Belanger S, et al.New roles for matrix metalloproteinases in metastasis CRITICAL REVIEWS IN IMMUNOLOGY 25 (6): 493-523 2005 23. Kuivanen T, Ahokas K, Virolainen S, et al.MMP-21 is upregulated at early stages of melanoma progression but disappears with more aggressive phenotype VIRCHOWS ARCHIV 447 (6): 954-960 DEC 2005 24. Sorensen KC, Newman RG, Kitchell BE, et al.Isolation, characterization, and expression of stromelysin-1 in primary tumors of dogs AMERICAN JOURNAL OF VETERINARY RESEARCH 66 (9): 1526-1535 SEP 2005 25. Zucker S, Cao J Measurement of matrix metaloproteinases in serum of patients with melanoma: Snarled in technical pitfalls CLINICAL CANCER RESEARCH 11 (14): 5069-5070 JUL 15 2005 26. Tas F, Duranyildiz D, Oguz H, et al.Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma MEDICAL ONCOLOGY 22 (1): 39- 44 2005 27. Carlson JA, Ross JS, Slominski A, et al.Molecular diagnostics in melanoma JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 52 (5): 743-775 MAY 2005 16 28. Hofmann UB, Houben R, Brocker EB, et al.Role of matrix metalloproteinases in melanoma cell invasion BIOCHIMIE 87 (3-4): 307-314 MAR-APR 2005 29. Loffek S, Zigrino P, Angel P, et al.High invasive melanoma cells induce matrix metalloproteinase-1 synthesis in fibroblasts by interleukin-1 alpha and basic fibroblast growth factor-mediated mechanisms JOURNAL OF INVESTIGATIVE DERMATOLOGY 124 (3): 638-643 MAR 2005 30. Jordan RCK, Macabeo-Ong M, Shiboski CH, et al.Overexpression of matrix metalloproteinase- 1 and-9 mRNA is associated with progression of oral dysplasia to cancer CLINICAL CANCER RESEARCH 10 (19): 6460-6465 OCT 1 2004 31. Van Themsche C, Alain T, Kossakowska AE, et al.Stromelysin-2 (matrix metalloproteinase 10) is inducible in lymphoma cells and accelerates the growth of lymphoid tumors in vivo JOURNAL OF IMMUNOLOGY 173 (6): 3605-3611 SEP 15 2004 32. Huntington JT, Shields JM, Der CJ, et al.Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells - Role of BRAF mutation and fibroblast growth factor signaling JOURNAL OF BIOLOGICAL CHEMISTRY 279 (32): 33168-33176 AUG 6 2004 33. Baba M, Itoh K, Tatsuta MGlycine-extended gastrin induces matrix metalloproteinase-1-and-3- mediated invasion of human colon cancer cells through type I collagen gel and matrigel INTERNATIONAL JOURNAL OF CANCER 111 (1): 23-31 AUG 10 2004 34. Ntayi C, Hornebeck W, Bernard PInvolvement of matrix metalloproteinases (MMPs) in cutaneous melanoma progression PATHOLOGIE BIOLOGIE 52 (3): 154-159 APR 2004 35. Labrousse AL, Ntayi C, Hornebeck W, et al.Stromal reaction in cutaneous melanoma CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 49 (3): 269-275 MAR 2004 36. Borghaei RC, Rawlings PL, Javadi M, et al.NF-kappa B binds to a polymorphic repressor element in the MMP-3 promoter BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 316 (1): 182-188 MAR 26 2004 37. Riedlinger G, Kridel S, Al-Housseini AM, et al.Metastatic melanoma and matrix metalloproteinases DRUGS OF THE FUTURE 28 (9): 897-904 SEP 2003 38. Sorensen KC, Kitchell BE, Siegel AM, et al.Isolation, characterization, and expression of feline stromelysin-1 in naturally developing tumors in cats AMERICAN JOURNAL OF VETERINARY RESEARCH 65 (2): 213-219 FEB 2004 39. Smolarz, B., Szyłł, K., Romanowicz-Makowska, H., Niewiadomski, M., Kozłowska, E., Kulig, A. PCR Analysis of Matrix Metalloproteinase 3 (MMP-3) Gene Promoter Polymorphism in Ovarian Cancer Polish Journal of Pathology 54 (4), pp. 233-238, 2003 40. Sulaimon SS, Kitchell BEThe basic biology of malignant melanoma: Molecular mechanisms of disease progression and comparative aspects JOURNAL OF VETERINARY INTERNAL MEDICINE 17 (6): 760-772 NOV-DEC 2003 41. Keehn CA, Smoller BR, Morgan MB Expression of the Ets-1 proto-oncogene in melanocytic lesions MODERN PATHOLOGY 16 (8): 772-777 AUG 2003 42. Guenzi E, Topolt K, Lubeseder-Martellato C, et al.The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression EMBO JOURNAL 22 (15): 3772-3782 AUG 1 2003 43. Fingleton BMatrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects EXPERT OPINION ON THERAPEUTIC TARGETS 7 (3): 385-397 JUN 2003 44. Nwankwo JO Anti-metastatic activities of all-trans retinoic acid, indole-3-carbinol and (+)- catechin in Dunning rat invasive prostate adenocarcinoma cells ANTICANCER RESEARCH 22 (6C): 4129-4135 NOV-DEC 2002 45. Enrique Carrillo de Santa Pau, PhD thesis, Estudio de neoangiogénesis y expresión génica diferencial en pacientes con cáncer de pulmón , Actualmente, el cáncer de pulmón es la novena causa de fallecimiento en el mundo y se estima que en el año 2030 habrá subido hasta el sexto 17 puesto. El cáncer de pulmón es la principal causa de muerte por cáncer, produciendo 1.3 millones de fallecimientos ... [www.ucm.es/eprints/7518/], 2007, http://www.ucm.es/BUCM/tesis/bio/ucm-t29753.pdf 46. Pastila R., PhD thesis. EFFECT OF LONG-WAVE UV RADIATION ON MOUSE MELANOMA: AN IN VITRO AND IN VIVO STUDY. University of Helsinki, Faculty of Biosciences, 2006. https://oa.doria.fi/bitstream/handle/10024/488/effectof.pdf?sequence=1 47. Svetlana Tsareva, PhD thesis, Origins and consequences of persistent stat3 activation in colorectal carcinoma cells Univ., Diss., 2005--Jena [www.db-thueringen.de/.../Dissertation_Tsareva.pdf] 48. Stefanie Löffek, PhD thesis, Die Regulation und Aktivierung von Matrix-Metalloproteinasen durch Interaktionen von humanen Melanomzellen mit dermalen ... Univ., Diss., 2005--Köln [kups.ub.uni-koeln.de/.../Loeffek_Doktorarbeit.pdf] 49. Suvi Ilmonen. PhD Thesis: PROGNOSTIC FACTORS OF PRIMARY CUTANEOUS MELANOMA, Helsinki 2005 50. Tiina Kuivanen, PhD Thesis: Matrix metalloproteinases as biomarkers in premalignant and malignant tumors of the human skin, Helsinki 2008

BOOKS 51. Cancer and inflammation, Douglas W. Morgan,Ulf Forssmann,Marian T. Nakada., Birkhauser Varlag, Basel – Boston - Berlin, 2004

52. Patent: REGULATION OF MATRIX METALLOPROTEINASE (MMP) GENE EXPRESSION IN TUMOR CELLS VIA THE APPLICATION OF ELECTRIC AND/OR ELECTROMAGNETIC FIELDS, BRIGHTON, Carl T. Methods and apparatus provide for treating and/or preventing tumor growth and/orspread, and/or other conditions in which Matrix Metalloproteinase (MMP) proteinhas been implicated in a patient, comprising generating at least one specificand selective ... Patent record available from the World Intellectual Property Organization (WIPO), 2009

53. IMINOSUGAR TREATMENT OF TUMORS DWEK, Raymond, BUZGARIU, Wanda, HIRTOPEANU, Anca, MORIARTY, Robert, NEGROIU, Gabriela, NICHITA, Norica, ZDRENTU, Livia, ZITZMANN, Nicole A proliferation of cells can be reduced by contacting the cells with a compound having formula (I). where R and R are each alkyl groups, R" is hydrogen or an alkyl group and X 3 , X 4 and X 5 are each independently selected from the group consisting of ... Patent record available from the World Intellectual Property Organization (WIPO), 2008

54. Patent: IDENTIFICATION OF RAC1B AS A MARKER AND MEDIATOR OF MATRIX METALLOPROTEINASE-INDUCED MALIGNANCY RADISKY, Derek C., NELSON, Celeste M., BISSELL, Mina J. The present invention provides compositions and methods for detecting MMP-induced malignancies by detecting Rac1b expression. The invention further provides compositions and in vitro and in vivo methods for inhibiting MMP-induced malignant transformation ... Patent record available from the World Intellectual Property Organization (WIPO), 2006

5. Цитирана статия Vascularity and prognosis of metastatic melanoma VLAYKOVA T, MUHONEN T, HAHKAKEMPPINEN M, et al. INTERNATIONAL JOURNAL OF CANCER 74 (3): 326-329 JUN 20 1997 18 1. Chua, R., Setzer, S., Govindarajan, B., Sexton, D., Cohen, C., Arbiser, J.L. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. Journal of the American Academy of Dermatology, 60 (5) pp. 758-766, 2009 2. Payette, M.J., Katz III, M., Grant-Kels, J.M. Melanoma prognostic factors found in the dermatopathology report. Clinics in Dermatology, 27 (1) pp. 53-74. 2009

3. Tang, HW; Wang, J; Bai, FH; Zhai, HH; Gao, J; Hong, L; Xie, HH; Zhang, FM; Lan, M; Yao, WZ; Liu, J; Wu, KC; Fan, DM. Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer. CANCER INVESTIGATION 26 (1): 60-67 2008 4. Hillen, F; van de Winkel, A; Creytens, D; Vermeulen, AHM; Griffioen, AW. Proliferating endothelial cells, but not microvessel density, are a prognostic parameter in human cutaneous melanoma. MELANOMA RESEARCH 16 (5): 453-457 OCT 2006 5. Darom A, Gomatos IP, Leandros E, et al.Molecular markers (PECAM-1, ICAM-3, HLA-DR) determine prognosis in primary non-Hodgkinrs gastric lymphoma patients WORLD JOURNAL OF GASTROENTEROLOGY 12 (12): 1924-1932 MAR 28 2006 6. Saito Y, Sunamura M, Motoi F, et al.Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region CANCER GENE THERAPY 13 (3): 242- 252 MAR 2006 7. Valencak J, Heere-Ress E, Kopp T, et al.Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma EUROPEAN JOURNAL OF CANCER 40 (3): 358-364 FEB 2004 8. Duda DG, Sunamura M, Lefter LP, et al.Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells ONCOGENE 22 (44): 6857-6864 OCT 9 2003 9. Keehn CA, Smoller BR, Morgan MBExpression of the Ets-1 proto-oncogene in melanocytic lesions MODERN PATHOLOGY 16 (8): 772-777 AUG 2003 10. Cohen C, Zavala-Pompa A, Sequeira JH, et al.Mitogen-actived protein kinase activation is an early event in melanoma progression CLINICAL CANCER RESEARCH 8 (12): 3728-3733 DEC 2002 11. Hlatky L, Hahnfeldt P, Folkman J Clinical application of antiangiogenic therapy: Microvessel density, what it does and doesn't tell us JOURNAL OF THE NATIONAL CANCER INSTITUTE 94 (12): 883-893 JUN 19 2002 12. Duda DG, Sunamura M, Lozonschi L, et al.Overexpression of the p53-inducible brain- specific angiogenesis inhibitor 1 suppresses efficiently tumour angiogenesis BRITISH JOURNAL OF CANCER 86 (3): 490-496 FEB 1 2002 13. Mattern JRole of angiogenesis in drug resistance ANTICANCER RESEARCH 21 (6B): 4265-4270 NOV-DEC 2001 14. Schroeder RJ, Hauff P, Bartels T, et al.Tumor vascularization in experimental melanomas: Correlation between unenhanced and contrast enhanced power Doppler imaging and histological grading ULTRASOUND IN MEDICINE AND BIOLOGY 27 (6): 761-771 JUN 2001 15. Reed JA, Albino APUpdate of diagnostic and prognostic markers in cutaneous malignant melanoma CLINICS IN LABORATORY MEDICINE 20 (4): 817+ DEC 2000 16. Gulubova MV Ito cell morphology, alpha-smooth muscle actin and collagen type IV expression in the liver of patients with gastric and colorectal tumors HISTOCHEMICAL JOURNAL 32 (3): 151-164 MAR 2000 17. Straume O, Salvesen HB, Akslen LA Angiogenesis is prognostically important in vertical growth phase melanomas INTERNATIONAL JOURNAL OF ONCOLOGY 15 (3): 595-599 SEP 1999 19 18. Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, et al.Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma ACTA ONCOLOGICA 38 (5): 549-557 1999 19. Reed JA, Albino AP Update of diagnostic and prognostic markers in cutaneous malignant melanoma DERMATOLOGIC CLINICS 17 (3): 631+ JUL 1999 20. Fonsatti E, Lamaj E, Coral S, et al.In vitro analysis of the melanoma endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells CANCER IMMUNOLOGY IMMUNOTHERAPY 48 (2-3): 132-138 MAY-JUN 1999 21. Micaela Hernberg Lymphocyte subsets and prognosis of patients receiving interferon for melanoma or renal cell carcinoma PhD thesis book Dept. Oncology and Radiotherapy, Helsinki University Central Hospital, University of Helsinki, 1998 22. Carmen Claudia Abel, phD-Thesis: Immunhistochemische Untersuchungen zur Expression von von Willebrand Faktor und PECAM-1 durch humane pulmonale Endothelzellen, Aus dem Institut für Pathologie der Ruhr-Universität Bochum, Bochum, 2005 23. Judah Folkman. Tumor Angiogenesis in Cancer Medicine, 6th Edition, 2000 (http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed.biblist.2310) 24. Shepard, Michael H. (US) Groziak, Michael P. (US) European Patent EP1167972, Enzyme catalyzed therapeutic agents, (http://www.freepatentsonline.com/EP1167972.html)

6. Цитирана статия Changes in serum ceruloplasmin activity after whole body irradiation of mammals ALADJOV E, VLAYKOVA T JOURNAL OF RADIATION RESEARCH 38 (3): 157-163 SEP 1997

1. Koterov A. N., Sidorovich G. I., RAZNONAPRAVLENNOE IZMENENIE ANTIOKSIDANTNOI AKTIVNOSTI V PLAZME (SYVOROTKE) KROVI MLEKOPITAYuShchIKh POSLE VOZDEISTVIYa RADIATsII V BOL'ShOI I MALOI DOZE, Radiatsionnaya biologiya. Radioekologiya, tom 49, № 6, Noyabr'-Dekabr' 2009, S. 671- 680 2. Yilmaz A, Sari RA, Gundogdu M, et al.Trace elements and some extracellular antioxidant proteins levels in serum of patients with systemic lupus erythematosus CLINICAL RHEUMATOLOGY 24 (4): 331-335 AUG 2005 3. Assemand E, Lacroix M, Mateescu MA Caeruloplasmin sterilized by gamma-irradiation in the presence of L-tyrosine maintains structural and catalytic characteristics BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY 38: 143-149 Part 2 OCT 2003 4. Koc M, Taysi S, Sezen O, et al.Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy BIOLOGICAL & PHARMACEUTICAL BULLETIN 26 (10): 1494-1497 OCT 2003 5. Taysi S, Akcay F, Uslu C, et al.Trace elements and some extracellular antioxidant protein levels in serum of patients with laryngeal cancer BIOLOGICAL TRACE ELEMENT RESEARCH 91 (1): 11-18 JAN 2003 6. Cogalgil S, Taysi S Levels of antioxidant proteins and soluble intercellular adhesion molecule-1 in serum of patients with rheumatoid arthritis ANNALS OF CLINICAL AND LABORATORY SCIENCE 32 (3): 264-270 SUM 2002

7. Цитирана статия Integrin chains beta 1 and alpha v as prognostic factors in human metastatic melanoma NIKKOLA J, VIHINEN P, VLAYKOVA T, et al. MELANOMA RESEARCH 20 14 (1): 29-37 FEB 2004 1. Wang, Y., Jiang, H., Dai, D., Su, M., Martinka, M., Brasher, P., Zhang, Y., McLean, D., Zhang, J., Ip, W., Li, G., Zhang, X., Zhou, Y. Alpha 1 antichymotrypsin is aberrantly expressed during melanoma progression and predicts poor survival for patients with metastatic melanoma. Pigment Cell and Melanoma Research, 23 (4) pp. 575-578. 2010 2. Kaufman, K.L., Belov, L., Huang, P., Mactier, S., Scolyer, R.A., Mann, G.J., Christopherson, R.I. An extended antibody microarray for surface profiling metastatic melanoma. Journal of Immunological Methods, 358 (1-2) pp. 23-34. 2010 3. Liu, JF; Fong, YC; Chang, CS; Huang, CY; Chen, HT; Yang, WH; Hsu, CJ; Jeng, LB; Chen, CY; Tang, CH. Cyclooxygenase-2 enhances alpha 2 beta 1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. MOLECULAR CANCER 9: Art. No. 43 FEB 23 2010. 4. Yang, WH; Chang, JT; Hsu, SF; Li, TM; Cho, DY; Huang, CY; Fong, YC; Tang, CH. Bradykinin Enhances Cell Migration in Human Chondrosarcoma Cells Through BK Receptor Signaling Pathways. JOURNAL OF CELLULAR BIOCHEMISTRY 109 (1): 82-92 JAN 1 2010.

Преди15.01.2010 5. Lee, H.J., Shon, C.H., Kim, Y.S., Kim, S., Kim, G.C., Kong, M.G. Degradation of adhesion molecules of G361 melanoma cells by a non-thermal atmospheric pressure microplasma. New Journal of Physics, 11, art. no. 115026, 2009 6. Lesniak, D; Xu, YX; Deschenes, J; Lai, R; Thoms, J; Murray, D; Gosh, S; Mackey, JR; Sabri, S; Abdulkarim, B. Beta(1)-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer. CANCER RESEARCH 69 (22): 8620-8628 NOV 15 2009. 7. Tang, C.-H., Lu, M.-E.. Adiponectin increases motility of human prostate cancer cells via AdipoR, p38, AMPK, and NF-κB pathways. Prostate, 69 (16) pp. 1781-1789, 2009 8. Chiu, YC; Shieh, DC; Tong, KM; Chen, CP; Huang, KC; Chen, PC; Fong, YC; Hsu, HC; Tang, CH. Involvement of AdipoR receptor in adiponectin-induced motility and alpha 2 beta 1 integrin upregulation in human chondrosarcoma cells. CARCINOGENESIS 30 (10): 1651-1659 OCT 2009. 9. Tsukamoto, H; Kato, T; Enomoto, A; Nakamura, N; Shimono, Y; Jijiwa, M; Asai, N; Murakumo, Y; Shibata, K; Kikkawa, F; Takahashi, M. Expression of Ret finger protein correlates with outcomes in endometrial cancer. CANCER SCIENCE 100 (10): 1895-1901 OCT 2009. 10. Meads, MB; Gatenby, RA; Dalton, WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. NATURE REVIEWS CANCER 9 (9): 665-A674 SEP 2009 11. Su, CM; Lu, DY; Hsu, CJ; Chen, HT; Huang, CY; Yang, WH; Su, YC; Yang, SN; Fong, YC; Tseng, WP; Tang, CH. Glial Cell-Derived Neurotrophic Factor Increases Migration of Human Chondrosarcoma Cells Via ERK and NF-kappa B Pathways. JOURNAL OF CELLULAR PHYSIOLOGY 220 (2): 499-507 AUG 2009. 12. Yang, SN; Chen, HT; Tsou, HK; Huang, CY; Yang, WH; Su, CM; Fong, YC; Tseng, WP; Tang, CH. Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor. CARCINOGENESIS 30 (4): 566-574 APR 2009. 13. Rothberg, BEG; Bracken, MB; Rimm, DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. JOURNAL OF THE NATIONAL CANCER INSTITUTE 101 (7): 452-474 APR 1 2009 14. Lu JG, Sun YN, Wang C, Jin de J, Liu M. Role of the αv-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation, Eur Arch Otorhinolaryngol. 2009 Jan;266(1):89-96. Epub 2008 Apr 22 21 15. Bachmann, IM; Ladstein, RG; Straume, O; Naumov, GN; Akslen, LA. Tumor necrosis is associated with increased alpha(v)beta(3) integrin expression and poor prognosis in nodular cutaneous melanomas. BMC CANCER 8: Art. No. 362 DEC 5 2008 16. Rodriguez, FJ; Giannini, C; Asmann, YW; Sharma, MK; Perry, A; Tibbetts, KM; Jenkins, RB; Scheithauer, BW; Anant, S; Jenkins, S; Eberhart, CG; Sarkaria, JN; Gutmann, DH. Gene Expression Profiling of NF-1-Associated and Sporadic Pilocytic Astrocytoma Identifies Aldehyde Dehydrogenase I Family Member L1 (ALDHIL1) as an Underexpressed Candidate Biomarker in Aggressive Subtypes. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY 67 (12): 1194-1204 DEC 2008 17. Fong, YC; Li, TM; Wu, CM; Hsu, SF; Kao, ST; Chen, RJ; Lin, CC; Liu, SC; Wu, CL; Tang, CH. BMP-2 Increases Migration of Human Chondrosarcoma Cells Via P13K/Akt Pathway. JOURNAL OF CELLULAR PHYSIOLOGY 217 (3): 846-855 DEC 2008 18. Yi-Chin Fong 1 2 3, Te-Mao Li 4, Chi-Ming Wu 4, Sheng-Feng Hsu 4, Shung-Te Kao 1 3, Ray- Jade Chen 5, Cheng-Chieh Lin 6, Shan-Chi Liu 7, Chien-Lin Wu 4, Chih-Hsin Tang, BMP-2 increases migration of human chondrosarcoma cells via PI3K/Akt pathway, JOURNAL OF CELLULAR PHYSIOLOGY, Volume 217 Issue 3, Pages 846 – 855, 2008. 19. Shaikh, FM; Seales, EC; Clem, WC; Hennessy, KM; Zhuo, Y; Bellis, SL. Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms. EXPERIMENTAL CELL RESEARCH 314 (16): 2941-2950 OCT 1 2008 20. Schmidmaier, R; Baumann, P. ANTI-ADHESION evolves to a promising therapeutic concept in oncology. CURRENT MEDICINAL CHEMISTRY 15 (10): 978-990 APR 2008. 21. Orimoto, AM; Festa, C; Plmentel, ERA; Sanches, JA; Sotto, MN; Akaishi, E; Ruiz, IRG High numbers of human skin cancers express MMP2 and several integrin genes. JOURNAL OF CUTANEOUS PATHOLOGY 35 (3): 285-291 MAR 2008 22. Crowson, AN; Magro, C; Miller, A; Mihm, MC. he molecular basis of melanomagenesis and the metastatic phenotype. SEMINARS IN ONCOLOGY 34 (6): 476-490 DEC 2007. 23. Wenke, AK; Kjellman, C; Lundgren-Akerlund, E; Uhlmann, C; Haass, NK; Herlyn, M; Bosserhoff, AK. Expression of integrin alpha 10 is induced in malignant melanoma. CELLULAR ONCOLOGY 29 (5): 373-386 2007 24. Yao, ES; Zhang, H; Chen, YY; Lee, B; Chew, K; Moore, D; Park, C. Increased beta(1) integrin is associated with decreased survival in invasive breast cancer. CANCER RESEARCH 67 (2): 659-664 JAN 15 2007 25. Christina L Addison. Modulation of response to tumor therapies by the extracellular matrix. FUTURE ONCOLOGY, June 2006, Vol. 2, No. 3, Pages 417-429 (doi: 10.2217/14796694.2.3.417) 26. Nakahata AM, Bueno NR, Rocha HAO, et al.Structural and inhibitory properties of a plant proteinase inhibitor containing the RGD motif INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES 40 (1): 22-29 DEC 15 2006 27. Bewick MA, Lafrenie RMAdhesion dependent signalling in the tumour microenvironment: The future of drug targetting CURRENT PHARMACEUTICAL DESIGN 12 (22): 2833-2848 2006 28. Sadej R, Spychala J, Skladanowski ACExpression of ecto-5 '-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma MELANOMA RESEARCH 16 (3): 213-222 JUN 2006 29. Hoon DSB, Kitago M, Kim J, et al.Molecular mechanisms of metastasis CANCER AND METASTASIS REVIEWS 25 (2): 203-220 JUN 2006 30. Addison, C.L. Modulation of response to tumor therapies by the extracellular matrix. Future Oncology 2 (3), pp. 417-429, 2006 31. Bosserhoff AK Novel biomarkers in malignant melanoma CLINICA CHIMICA ACTA 367 (1- 2): 28-35 MAY 2006 32. Bauer R, Humphries M, Fassler R, et al.Regulation of integrin activity by MIA JOURNAL OF BIOLOGICAL CHEMISTRY 281 (17): 11669-11677 APR 28 2006 22 33. Cranmer LD, Trevor KT, Bandlamuri S, et al.Rodent models of brain metastasis in melanoma MELANOMA RESEARCH 15 (5): 325-356 OCT 2005 34. Kuphal S, Bauer R, Bosserhoff AK Integrin signaling in malignant melanoma CANCER AND METASTASIS REVIEWS 24 (2): 195-222 JUN 2005 35. Haass NK, Smalley KSM, Li L, et al.Adhesion, migration and communication in melanocytes and melanoma PIGMENT CELL RESEARCH 18 (3): 150-159 JUN 2005 36. Frank NY, Margaryan A, Huang Y, et al.ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma CANCER RESEARCH 65 (10): 4320-4333 MAY 15 2005 37. Poole K, Muller D Flexible, actin-based ridges colocalise with the beta 1 integrin on the surface of melanoma cells BRITISH JOURNAL OF CANCER 92 (8): 1499-1505 APR 25 2005 38. Serra Muxн, Montserrat, PhD Thesis, Versicà, CD44 i àcid hialurònic en el melanoma humà i caní. Implicacions funcionals del complex En la present tesi un dels primers objectius era caracteritzar el model caní per tal d'avaluar les seves similituds amb el melanoma humà. En aquest sentit, el primer que es va descriure va ser la caracterització de tres línies de melanoma caní (CML-1, ... , [www.tdx.cesca.es/TDX-1010105- 183346/], 2005 39. Richard Bauer, PhD Thesis, Aspekte der Zell-Zell- und Zell-Matrix-Interaktion im malignen Melanom , Regensburg, Univ., Diss., 2005. [www.opus-bayern.de/.../Doktorarbeit%20fertig2.pdf] 40. Daniela Gast, PhD Thesis, Die Rolle des Zelladhäsionsmoleküls L1 in der Tumorprogression , Univ., Diss., 2006--Kassel [deposit.d-nb.de/cgi-bin/dokserv?idn=98096301X] 41. Patent record, INTEGRIN ALPHA-10 SUBUNIT AS THERAPEUTIC TARGET AND DIAGNOSTIC/PROGNOSTIC MARKER FOR CANCER LUNDGREN-ÅKERLUND, Evy, BOSSERHOFF, Anja (WO/2007/107774) The present invention provides the use of a compound comprising a binding moiety capable of binding selectively to integrin alpha- 10 subunit or a heterodimer thereof in the preparation of a (a) a medicament for treating malignant tumours, (b) a ... Patent record available from the World Intellectual Property Organization (WIPO), 2007 42. CEFAM - PROJECT DESCRIPTION, PROJECT DESCRIPTION, METHODOLOGY, AND EXPECTED RESULTS www.kpk.gov.pl/7pr/eoi/ideas/getfile.html?id=115165900522182

8. Цитирана статия High collagenase-1 expression correlates with a favourable chemoimmunotherapy response in human metastatic melanoma NIKKOLA J, VIHINEN P, VLAYKOVA T, et al. MELANOMA RESEARCH, 11 (2): 157-166 2001

1. Rothberg, BEG; Rimm, DL. Biomarkers: The Useful and the Not So Useful- An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY 130 (8): 1971-1987 AUG 2010 2. Zigrino, P., Kuhn, I., Bäuerle, T., Zamek, J., Fox, J.W., Neumann, S., Licht, A., Schorpp- Kistner, M., Angel, P., Mauch, C. Stromal expression of MMP-13 is required for melanoma invasion and metastasis. Journal of Investigative Dermatology, 129 (11) pp. 2686-2693. 2009 3. Bourguet, E; Sapi, J; Emonard, H; Hornebeck, W. Control of Melanoma Invasiveness by Anticollagenolytic Agents: A Reappraisal of an Old Concept. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY 9 (5): 576-597 JUN 2009. 23 4. Mannello, F. Natural bio-drugs as matrix metalloproteinase inhibitors: New perspectives on the horizon?. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY 1 (1): 91-103 JAN 2006 5. Nelson KK, Subbaram S, Connor KM, et al.Redox-dependent matrix metalloproteinase-1 expression is regulated by JNK through ets and AP-1 promoter motifs JOURNAL OF BIOLOGICAL CHEMISTRY 281 (20): 14100-14110 MAY 19 2006 6. Leivonen SK, Ala-aho R, Koli K, et al.Activation of Smad signaling enhances collagenase-3 (MMP-13) expression and invasion of head and neck squamous carcinoma cells ONCOGENE 25 (18): 2588-2600 APR 2006 Times Cited: 2 7. Corte MD, Gonzalez LO, Corte MG, et al.Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS 20 (4): 242-248 OCT-DEC 2005 8. Saunders WB, Bayless KJ, Davis GEMMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices JOURNAL OF CELL SCIENCE 118 (10): 2325-2340 MAY 15 2005 9. Hafner C, Breiteneder H, Ferrone S, et al.Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody INTERNATIONAL JOURNAL OF CANCER 114 (3): 426-432 APR 10 2005 10. Nelson KK, Melendez JAMitochondrial redox control of matrix metalloproteinases FREE RADICAL BIOLOGY AND MEDICINE 37 (6): 768-784 SEP 15 2004 11. Levinson H, Sil AK, Conwell JE, et al.Alpha V integrin prolongs collagenase production through jun activation binding protein 1 ANNALS OF PLASTIC SURGERY 53 (2): 155-161 AUG 2004 12. Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: Lessons learned from clinical trials and future directions. Critical Care Medicine. Introduction to the Third Margaux Conference on Critical Illness: The Endothelium-An Underrecognized Organ in Critical Illness?. 30(5) Supplement:S332-S340, May 2002 13. Ala-aho, Human collagenas3-3 (MMP-13) in tumor growth and invasion, PhD thesis book, Turku University, 2002 14. Carrillo de Santa Pau, Enrique PhD Thesis, (2007) Estudio de neoangiogénesis y expresión génica diferencial en pacientes con cáncer de pulmón. Tesis Doctoral. Tesis de la Universidad Complutense de MadridURL Oficial: http://www.ucm.es/BUCM/tesis/bio/ucm-t29753.pdf 15. Svetlana Tsareva, PhD Thesis, (2005), ORIGINS AND CONSEQUENCES OF PERSISTENT STAT3 ACTIVATION IN COLORECTAL CARCINOMA CELLS, Friedrich-Schiller- Universität Jena, [www.db-thueringen.de/.../Dissertation_Tsareva.pdf] 16. Stefanie Löffek, PhD Thesis, (2005), Die Regulation und Aktivierung von Matrix- Metalloproteinasen durch Interaktionen von humanen Melanomzellen mit dermalen ... Univ., Diss., 2005--Köln, [kups.ub.uni-koeln.de/.../Loeffek_Doktorarbeit.pdf]

Патенти 17. METHOD FOR DETERMINING IMMUNE SYSTEM AFFECTING COMPOUNDS HÅKANSSON, Leif, HÅKANSSON, Annika, CLINCHY, Birgitta The present invention relates to a method for increasing efficacy and/or possibility of therapeutic treatment of cancer, wherein any dys- regulatory mechanism, including inducing factor/s, of the production of immunoregulatory substances, including one or ... Patent record available from the World Intellectual Property Organization (WIPO), 2003

9. Цитирана статия Prognostic value of beta 1 integrin expression in metastatic melanoma VIHINEN P, NIKKOLA J, VLAYKOVA T, et al. 24 MELANOMA RESEARCH 10 (3): 243-251 JUN 2000 1. Yoshida, S; Takahashi, H. Expression of Extracellular Matrix Molecules in Brain Metastasis. JOURNAL OF SURGICAL ONCOLOGY 100 (1): 65-68 JUL 1 2009. 2. Rothberg, BEG; Bracken, MB; Rimm, DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. JOURNAL OF THE NATIONAL CANCER INSTITUTE 101 (7): 452-474 APR 1 2009

1* 2 3 4 3. Rishab K. Gupta , Alistair J. Cochran , Eddy C. Hsueh , Steven D. Trocha , Donald L. Morton, NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic Melanoma (Section 3L) 1 National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Malignant Melanoma,1-42 2008 4. Crowson, A.N., Magro, C., Miller, A., Mihm Jr., M.C. The Molecular Basis of Melanomagenesis and the Metastatic Phenotype. Seminars in Oncology 34 (6), pp. 476-490, 2007 5. Cheng, G., Li, B., Wang, W., Sun, X., Li, L., Gao, F. Effect of integrin β1 and MMPs on invasion and metastasis of choroidal melanoma, Chinese Ophthalmic Research 25 (2), pp. 109-112, 2007 6. Becker D, Mihm MC, Hewitt SM, et al.Markers and tissue resources for melanoma: Meeting report CANCER RESEARCH 66 (22): 10652-10657 NOV 15 2006 7. Lee I, Skinner MA, Guo HB, et al.Expression of the vacuolar H+-ATPase 16-kDa subunit results in the Triton X-100-insoluble aggregation of beta(1) integrin and reduction of its cell surface expression JOURNAL OF BIOLOGICAL CHEMISTRY 279 (51): 53007-53014 DEC 17 2004 8. Pasco S, Ramont L, Maquart FX, et al.Control of melanoma progression by various matrikines from basement membrane macromolecules CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 49 (3): 221-233 MAR 2004 9. Maubant S, Staedel C, Gauduchon PIntegrins, cell response to anti-tumor agents and chemoresistance BULLETIN DU CANCER 89 (11): 923-934 NOV 2002 Li N, Mangini J, Bhawan JNew prognostic factors of cutaneous melanoma: a review of the literature JOURNAL OF CUTANEOUS PATHOLOGY 29 (6): 324-340 JUL 2002 10. Rust WL, Carper SW, Plopper GE. The Promise of Integrins as Effective Targets for Anticancer Agents. J Biomed Biotechnol. 2002;2(3):124-130 11. Li, N., Mangini, J., Bhawan, J. New prognostic factors of cutaneous melanoma: A review of the literature, Journal of Cutaneous Pathology 29 (6), pp. 324-340, 2002 12. Naomi Walsh B.Sc. Hons. PhD Thesis. Molecular mechanisms of drug resistance, invasion and metastasis in pancreatic carcinoma, 2007 http://doras.dcu.ie/141/1/walsh_naomi_2008.pdf 13. Bernward Gottfried Hinkes, PhD Thesis: Einfluß des Ca2+-sensitiven Kaliumkanals hIK1 auf die Migration humaner neutrophiler Granulozyten auf Fibronektin, Bayerischen Julius – Maximilians - Universität zu Würzburg, Würzburg, im Juli 2003, http://deposit.ddb.de/cgi- bin/dokserv?idn=969881096&dok_var=d1&dok_ext=pdf&filename=969881096.pdf 14. Yong Wei5 and Jessie L.-S. Au, Book chapter 17: Role of Tumour Microenvironment in Chemoresistance, In: Book series: Cancer Growth and Progression, V 15, Book: Integration/Interaction of Oncologic Growth, Edds. Hans E. Kaiser, Aejaz Nasir and Gary G. Meadows, Springer Netherlands, DOI 10.1007/1-4020-3414-8_17, 2006, p 285-321. 15. Thomas A. Gardner5, 6, 7, Juan Antonio Jiménez5, 6, 7, Leland W. K. Chung8 and Chinghai Kao5, In Book chapter: Antimetastatic Gene Therapy. Prostate Cancer Theory to Therapy, In Book series: Contemporary Cancer Research, In BOOK: Cancer Gene Therapy, Edds. David T. Curiel and Joanne T. Douglas, DOI 10.1007/978-1-59259-785-7_20, 2007. p. 299-319.

10. Цитирана статия Prognostic value of tumour vascularity in metastatic melanoma and association of blood vessel density with vascular endothelial growth factor expression VLAYKOVA T, LAURILA P, MUHONEN T, et al. MELANOMA RESEARCH 9 (1): 59-68 FEB 1999

1. Rodríguez, J.R.H., Quintela, I.P., Cortijo, G.P., Martínez, C.L., Corbacho, J.G., Aguilar, E.A. Platelet endothelial cell adhesion molecule (PECAM-1) expression in malignant human tumours and their metastases. Journal of Cancer Therapy, 1 (2) pp. 66-70., 2010 2. Rothberg, BEG; Rimm, DL. Biomarkers: The Useful and the Not So Useful- An Assessment of Molecular Prognostic Markers for Cutaneous Melanoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY 130 (8): 1971-1987 AUG 2010 3. Mehnert, J.M., McCarthy, M.M., Jilaveanu, L., Flaherty, K.T., Aziz, S., Camp, R.L., Rimm, D.L., Kluger, H.M. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Human Pathology, 41 (3) pp. 375-384. 2010 4. Cadili, A. The role of angiogenesis in melanoma metastasis. ANZ JOURNAL OF SURGERY 79 (11): 774-776 NOV 2009. 5. Bhat, P., Jakobiec, F.A., Folberg, R. Comparison of tumor-associated vasculatures in uveal and cutaneous melanomas. Seminars in Ophthalmology, 24 (3) pp. 166-171. 2009 6. Brantley-Sieders, D.M., Zhuang, G., Vaught, D., Freeman, T., Hwang, Y., Hicks, D., Chen, J. Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo. Molecular Cancer Research, 7 (5) pp. 615-623. 2009 7. Chua, R., Setzer, S., Govindarajan, B., Sexton, D., Cohen, C., Arbiser, J.L. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. Journal of the American Academy of Dermatology, 60 (5) pp. 758-766, 2009 8. Rothberg, BEG; Bracken, MB; Rimm, DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. JOURNAL OF THE NATIONAL CANCER INSTITUTE 101 (7): 452-474 APR 1 2009 9. Helfrich, I; Edler, L; Sucker, A; Thomas, M; Christian, S; Schadendorf, D; Augustin, HG. Angiopoietin-2 Levels Are Associated with Disease Progression in Metastatic Malignant Melanoma. CLINICAL CANCER RESEARCH 15 (4): 1384-1392 FEB 15 2009. 10. Payette, M.J., Katz III, M., Grant-Kels, J.M. Melanoma prognostic factors found in the dermatopathology report. Clinics in Dermatology, 27 (1) pp. 53-74. 2009 1* 2 3 4 11. Rishab K. Gupta , Alistair J. Cochran , Eddy C. Hsueh , Steven D. Trocha , Donald L. Morton, NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic Melanoma (Section 3L) 1 National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Malignant Melanoma,1-42 2008 12. Abe, R; Fujita, Y; Yamagishi, S; Shimizu, H. Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition. CURRENT PHARMACEUTICAL DESIGN 14 (36): 3802-3809 DEC 2008. 13. Patel, D; Bassi, R; Hooper, AT; Sun, H; Huber, J; Hicklin, DJ; Kang, XQ. Enhanced Suppression of Melanoma Tumor Growth and Metastasis by Combined Therapy with Anti- VEGF Receptor and Anti-TYRP-1/gp75 Monoclonal Antibodies. ANTICANCER RESEARCH 28 (5A): 2679-2686 SEP-OCT 2008. 14. Ng, L; Beer, TW; Murray, K. Vascular density has prognostic value in Merkel cell carcinoma. AMERICAN JOURNAL OF DERMATOPATHOLOGY 30 (5): 442-445 OCT 2008 26 15. Milsom, C; Yu, J; May, L; Magnus, N; Rak, J. Diverse roles of tissue factor-expressing cell subsets in tumor progression. SEMINARS IN THROMBOSIS AND HEMOSTASIS 34 (2): 170-181 MAR 2008 16. Molhoek, KR; Griesemann, H; Shu, JF; Gershenwald, JE; Brautigan, DL; Slingluff, CL. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. CANCER RESEARCH 68 (11): 4392-4397 JUN 1 2008. 17. Roy, S; Maity, P. Modulation of metastatic potential of B16F10 melanoma cells by acivicin: Synergistic action of glutaminase and Potentiation of cisplatin cytotoxicity. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 8 (2): 301-306 APR-JUN 2007 18. Tumeh, PC; Lerner, JM; Dicker, DT; El-Deiry, WS. Differentiation of vascular and non- vascular skin spectral signatures using in vivo hyperspectral radiometric imaging - Implications for monitoring angiogenesis. CANCER BIOLOGY & THERAPY 6 (3): 447-453 MAR 2007. 19. Olga Stępień-Wyrobiec, Grzegorz Wyrobiec,Wojciech Rokicki, Marzena Harabin-Słowińska, Naczyniowy czynnik wzrostu śrуdbłonka (VEGF) — regulator angiogenezy (Vascular endothelial growth factor (VEGF) — a regulator of angiogenesis) Ann. Acad. Med. Siles. 2007, 61, 2 20. Markovic SN, Suman VJ, Rao RA, et al. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS Volume: 30 Issue: 3 Pages: 303-309 Published: JUN 2007 21. Facchetti, F; Monzani, E; La Porta, CAM. New perspectives in the treatment of melanoma: Anti-angiogenic and anti-lymphangiogenic strategies. RECENT PATENTS ON ANTI- CANCER DRUG DISCOVERY 2 (1): 73-78 JAN 2007 22. Abe R, Fujita Y, Yamagishi S Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. MINI-REVIEWS IN MEDICINAL CHEMISTRY Volume: 7 Issue: 6 Pages: 649-661 Published: JUN 2007 23. Gille, J; Heidenreich, R; Pinter, A; Schmitz, J; Boehme, B; Hicklin, DJ; Henschler, R; Breier, G Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation INTERNATIONAL JOURNAL OF CANCER 2007 120(9):1899-908. 24. Brennecke S, Deichmann M, Naeher H, et al.Decline in angiogenic factors, such as interleukin- 8, indicates response to chemotherapy of metastatic melanoma MELANOMA RESEARCH 15 (6): 515-522 DEC 2005 25. Furstenberger G, von Moos R, Senn HJ, et al.Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis BRITISH JOURNAL OF CANCER 93 (7): 793-798 OCT 3, 2005 26. Hafner HM, Brauer K, Eichner M, et al.Wavelet analysis of cutaneous blood flow in melanocytic skin lesions JOURNAL OF VASCULAR RESEARCH 42 (1): 38-46 2005 27. Proniewska-Skre tek, E., Mariak, Z., Tumor angiogensis in uveal melanoma. Role of vascular endothelial growth factor (VEGF) | [Angiogeneza w nowotworach barwnikowych błony naczyniowej oka. Rola naczyniowo-śródbłonkowego czynnika wzrostu (VEGF)] Klinika Oczna 106 (4-5), pp. 682-685, 2004 28. Dadras SS, Detmar M Angiogenesis and lymphanglogenesis of skin cancers HEMATOLOGY- ONCOLOGY CLINICS OF NORTH AMERICA 18 (5): 1059+ OCT 2004 29. Peterson AC, Swiger S, Stadler WM, et al.Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma CLINICAL CANCER RESEARCH 10 (12): 4048-4054 Part 1 JUN 15 2004 30. Loggini B, Boldrini L, Gisfredi S, et al.CD34 microvessel density and VEGF expression in basal and squamous cell carcinoma PATHOLOGY RESEARCH AND PRACTICE 199 (11): 705-712 2003 27 31. Giatromanolaki A, Sivridis E, Kouskoukis C, et al.Hypoxia-inducible factors 1 alpha and 2 alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin MELANOMA RESEARCH 13 (5): 493-501 OCT 2003 32. Romanowska-Dixon B, Urbanska K, Elas M, et al.The histology of pigmented Bomirski melanoma growing in the hamster eye - Preliminary results CELLULAR & MOLECULAR BIOLOGY LETTERS 8 (3): 849-856, 2001 33. Bozena Romanowska-Dixon, Krystyna Urbanska, Martyna Elas, Stanislawa Pajak, Helena Zygulska-Mach and Adam Miodonski, Angiomorphology of the pigmented bomirski melanoma growing in hamster eye* ANNALS OF ANATOMY - ANATOMISCHER ANZEIGER, 183 (6), 2001, 559-565 34. Smoller BR New techniques in the diagnosis of primary cutaneous melanoma CURRENT PROBLEMS IN DERMATOLOGY-US 15 (5): 209-213 SEP-OCT 2003 35. Redondo P, Sanchez-Carpintero I, Bauza A, et al.Immunologic escape and angiogenesis in human malignant melanoma JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 49 (2): 255-263 AUG 2003 36. Streit M, Detmar M Angiogenesis, lymphangiogenesis, and melanoma metastasis ONCOGENE 22 (20): 3172-3179 MAY 19 2003 37. Dadras SS, Paul T, Bertoncini J, et al.Tumor lymphangiogenesis - A novel prognostic indicator for cutaneous melanoma metastasis and survival AMERICAN JOURNAL OF PATHOLOGY 162 (6): 1951-1960 JUN 2003 38. Hormbrey E, Gillespie P, Turner K, et al.A critical review of vascular endothelial growth factor (VEGF) analysis in peripheral blood: Is the current literature meaningful? CLINICAL & EXPERIMENTAL METASTASIS 19 (8): 651-663 2002 39. Malafa MP, Fokum FD, Smith L, et al.Inhibition of angiogenesis and promotion of melanoma dormancy by vitamin E succinate ANNALS OF SURGICAL ONCOLOGY 9 (10): 1023-1032 DEC 2002 40. Cheung KJ, Li G The tumour suppressor p33(1NG1) does not regulate migration and angiogenesis in melanoma cells INTERNATIONAL JOURNAL OF ONCOLOGY 21 (6): 1361-1365 DEC 2002 41. Ruiter DJ, Spatz A, van den Oord JJ, et al.Pathologic staging of melanoma SEMINARS IN ONCOLOGY 29 (4): 370-381 AUG 2002 42. Pennasilico GM, Arcuri PP, Laschena F, et al. Magnetic resonance imaging in the diagnosis of melanoma: in vivo preliminary studies with dynamic contrast-enhanced subtraction MELANOMA RESEARCH 12 (4): 365-371 AUG 2002 43. Howell WM, Bateman A, Turner SJ, et al.Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma GENES AND IMMUNITY 3 (4): 229-232 JUN 2002 44. McGough RL, Lin CZ, Meitner P, et al.Angiogenic cytokines in cartilage tumors CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (397): 62-69 APR 2002 45. McGough RL, Aswad BI, Terek RM Pathologic neovascularization in cartilage tumors CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (397): 76-82 APR 2002 46. Ruiter D, Bogenrieder T, Elder D, et al.Melanoma-stroma interactions: structural and functional aspects LANCET ONCOLOGY 3 (1): 35-43 JAN 2002 47. Indinnimeo M, Cicchini C, Stazi A, et al.Prognostic impact of CD31 antigen expression in anal canal carcinoma HEPATO-GASTROENTEROLOGY 48 (41): 1355-1358 SEP-OCT 2001 48. Zamolo G, Gruber F, Cabrijan L, et al.Influence of tumor thickness and vascularity on survival in cutaneous melanoma ACTA MEDICA OKAYAMA 55 (5): 289-293 OCT 2001 49. Schroeder RJ, Hauff P, Bartels T, et al.Tumor vascularization in experimental melanomas: Correlation between unenhanced and contrast enhanced power Doppler imaging and histological grading ULTRASOUND IN MEDICINE AND BIOLOGY 27 (6): 761-771 JUN 2001 28 50. Konopka TE, Barker JE, Bamford TL, et al.Nitric oxide synthase II gene disruption: Implications for tumor growth and vascular endothelial growth factor production CANCER RESEARCH 61 (7): 3182-3187 APR 1 2001 51. Sedlacek HH Pharmacological aspects of targeting cancer gene therapy to endothelial cells CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 37 (3): 169-215 MAR 2001 52. Poon RTP, Fan ST, Wong J Clinical implications of circulating angiogenic factors in cancer patients JOURNAL OF CLINICAL ONCOLOGY 19 (4): 1207-1225 FEB 15 2001 53. Janice P. Dutcher, Angiogenesis and Melanoma [abstract]. CURRENT ONCOLOGY REPORTS 2001, 3:353-358 54. Shigematsu, C., Masuda, H., Nemoto, N. Expression of vascular endothelial growth factor and basic fibroblast growth factor in liver metastatic lesions of fatty liver rats, Nihon University Journal of Medicine 42 (5), pp. 265-276, 2000 55. Cress AE Quantitation of phosphotyrosine signals in human prostate cell adhesion sites BIOTECHNIQUES 29 (4): 776+ OCT 2000 56. Johanna Nikkola Integrins and MMPs as prognostic factors in metastatic melanoma, PhD thesis book, Turku University, 2004 Dept. Oncology and Radiotherapy, Turku University Central Hospital, University of Turku 57. Graells Estrada, Jordi, PhD Thesis: Angiogènesi al Melanoma Maligne. Anàlisi de l’efecte de l’estimulació amb Matrigel, de la relació amb l’expressió del Factor de Creixement de l’Endoteli Vascular (VEGF) i de l’efecte de la transfecció del cDNA del VEGF en sentit i antisentit sobre l’angiogènesi i el comportament tumorals. Estudi en melanomes humans i en línies de melanoma humà xenoempeltades a ratolins immunodeprimits. PhD thesis book, UB,Spain, 2004, Dipòsit legal/ISBN: B.24017-2005 / 84-689-1997-7, [www.tdx.cesca.es/TDX- 0414105-093745/], 2005 58. Nicola Luz. Untersuchung der Gefäßdichte bei metastasierten und nicht-metastasierten Magenkarzinomen, PhD thesis book, 2003, Jülich, Germany, Techn. Hochsch., Diss., 2003—Aachen, [sylvester.bth.rwth-aachen.de/.../03_185.pdf] 59. Karri Paavonen, Vascular Endothelial Growth Factors and the Bmx Tyrosine Kinase in the Regulation of Angiogenesis and Lymphangiogenesis, , PhD thesis book, Helsinki University, 2003 60. Nicola Maruotti , Domenico Ribatti, The role of vascular endothelial growth factor in angiogenesis, Sociedad Iberoamericana de Información Científica (SIIC) http://www.siicsalud.com/dato/experto.php/90129, 2008 61. In BOOK: Tumor Markers, Physiology, Pathobiology, Thechnology, and Clinical Applications, Edd: Eleftherios P. Diamandis, Herbert A. Fritscher, Hans Lilja, Daniel W. Chan, Morton K. Schwartz, AACCPress, p372, 2002 http://books.google.bg/books?id=qwJHDfXMozUC&pg=RA1-PA372&lpg=RA1- PA372&dq=Vlaykova+T&source=web&ots=BSGvyP5lVC&sig=EFuewZcTH8GSuj47zEA_Fc DFLss&hl=bg&sa=X&oi=book_result&resnum=10&ct=result 62. In BOOK: VEGF and Cancer, Edd. Judith H. Harmey, p 53, Springer, 2004 http://books.google.bg/books?id=h7A74b_8x8cC&pg=PA53&lpg=PA53&dq=Vlaykova+T&so urce=web&ots=v7ds6E8aH9&sig=697t3b-3E1j-KI-Cnl- B634JtKo&hl=bg&sa=X&oi=book_result&resnum=5&ct=result#PPA53,M1

29 11. Цитирана статия Prognostic value of tumour vascularity in primary melanoma ILMONEN S, KARINIEMI AL, VLAYKOVA T, et al. MELANOMA RESEARCH 9 (3): 273-278 JUN 1999 1. Joan Figueroa, A., Díaz Anaya, A., Montero Leon, J.F., Jiménez Mendes, L. Some interesting prognostic factors related to cutaneous malignant melanoma. Revista Cubana de Cirugia, 49 (1), 2010 2. Helfrich, I; Scheffrahn, I; Bartling, S; Weis, J; von Felbert, V; Middleton, M; Kato, M; Ergun, S; Schadendorf, D. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. JOURNAL OF EXPERIMENTAL MEDICINE 207 (3): 491-503 MAR 15 2010. 3. Chen, LX; Zhang, SW; Li, XR; Sun, BC; Zhao, XL; Zhang, DF; Zhao, SZ. A pilot study of vasculogenic mimicry immunohistochemical expression in intraocular melanoma model. ONCOLOGY REPORTS 21 (4): 989-994 APR 2009 4. Payette, M.J., Katz III, M., Grant-Kels, J.M. Melanoma prognostic factors found in the dermatopathology report. Clinics in Dermatology, 27 (1) pp. 53-74. 2009 5. Antonicelli, F., Bellon, G., Debelle, L., Hornebeck, W. Elastin-Elastases and Inflamm- Aging . Current Topics in Developmental Biology 79, pp. 99-155, 2007. 6. Kiss, J; Timar, J; Somlai, B; Gilde, K; Fejos, Z; Gaudi, I; Ladanyi, A. Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma. PATHOLOGY & ONCOLOGY RESEARCH 13 (1): 21-31 2007 7. Humphrey, S; Walsh, NM; Delaney, L; Propperova, I; Langley, RGB. Prognostic significance of vascularity in cutaneous melanoma: Pilot study using in vivo confocal scanning laser microscopy. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY 10 (3): 122-127 MAY-JUN 2006 8. Stucker M, Springer C, Paech V, et al.Increased laser Doppler flow in skin tumors corresponds to elevated vessel density and reactive hyperemia SKIN RESEARCH AND TECHNOLOGY 12 (1): 1-6 FEB 2006 9. Zhang SW, Guo H, Zhang DF, et al.Microcirculation patterns in different stages of melanoma growth ONCOLOGY REPORTS 15 (1): 15-20 JAN 2006 10. Depasquale I, Thompson WD Microvessel density for melanoma prognosis HISTOPATHOLOGY 47 (2): 186-194 AUG 2005 11. Pelletier F, Bermont L, Puzenat E, et al.Circulating vascular endothelial growth factor in cutaneous malignant melanoma BRITISH JOURNAL OF DERMATOLOGY 152 (4): 685-689 APR 2005 12. Hafner HM, Brauer K, Eichner M, et al.Wavelet analysis of cutaneous blood flow in melanocytic skin lesions JOURNAL OF VASCULAR RESEARCH 42 (1): 38-46 2005 13. Kluk MJ, Grant-Kels JM, Kerr P, et al.Melanoma on the move: The progression of melanoma - Novel concepts with histologic correlates AMERICAN JOURNAL OF DERMATOPATHOLOGY 26 (6): 504-510 DEC 2004 14. Sun BC, Zhang SW, Zhao XL, et al.Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas INTERNATIONAL JOURNAL OF ONCOLOGY 25 (6): 1609-1614 DEC 2004 15. Dadras SS, Detmar M Angiogenesis and lymphanglogenesis of skin cancers HEMATOLOGY- ONCOLOGY CLINICS OF NORTH AMERICA 18 (5): 1059+ OCT 2004 16. Nguyen TH Mechanisms of metastasis CLINICS IN DERMATOLOGY 22 (3): 209-216 MAY- JUN 2004 17. Allias, M.A., Wårdell, K., Stücker, M., Anderson, C., Salerud, E.G., .Assessment of pigmented skin lesions in terms of blood perfusion estimates SKIN RESEARCH AND TECHNOLOGY 10 (1): 43-49 FEB 2004 30 18. Smoller BR New techniques in the diagnosis of primary cutaneous melanoma CURRENT PROBLEMS IN DERMATOLOGY-US 15 (5): 209-213 SEP-OCT 2003 19. Streit M, Detmar M Angiogenesis, lymphangiogenesis, and melanoma metastasis ONCOGENE 22 (20): 3172-3179 MAY 19 2003 20. Cohen C, Zavala-Pompa A, Sequeira JH, et al.Mitogen-actived protein kinase activation is an early event in melanoma progression CLINICAL CANCER RESEARCH 8 (12): 3728-3733 DEC 2002 21. Dome B, Paku S, Somlai B, et al.Vascularization of cutaneous melanoma involves vessel co- option and has clinical significance JOURNAL OF PATHOLOGY 197 (3): 355-362 JUL 2002 22. Massi, D., Franchi, A., Borgognoni, L., Paglierani, M., Reali, U.M., Santucci, M., Tumor angiogenesis as a prognostic factor in thick cutaneous malignant melanoma: A quantitative morphologic analysis, Virchows Archiv 440 (1), pp. 22-28, 2002 23. Saida T. Recent advances in melanoma research JOURNAL OF DERMATOLOGICAL SCIENCE 26 (1): 1-13 MAY 2001 24. Folberg R, Hendrix MJC, Maniotis AJ Vasculogenic mimicry and tumor angiogenesis AMERICAN JOURNAL OF PATHOLOGY 156 (2): 361-381 FEB 2000 25. Pinsolle, V., Ravaud, A., Baudet, J., Does surgery trigger metastasis spread in melanoma? | [La chirurgie favorise-t-elle le developpement de metastases dans les melanomes?] Annales de Chirurgie Plastique et Esthetique 45 (4), pp. 485-493, 2000 26. Christian Springer, PhD Thesis: Das histologische Korrelat der Laser-Doppler-Perfusion- Imager-Messung bei der Untersuchung von Hauttumoren Univ., Diss., 2006—Bochum, [www-brs.ub.ruhr-uni-bochum.de/.../diss.pdf] 27. Rüdiger Stefan Albrecht, PhD Thesis: Nicht lineare Analyse der kutanen Blutperfusion bei der Psoriasis vulgaris Univ., Diss., 2006--Tübingen, [w210.ub.uni- tuebingen.de/.../Dissertation_Albrecht_Ruediger.pdf] 28. Graells Estrada, Jordi, PhD Thesis: Angiogènesi al Melanoma Maligne. Anàlisi de l’efecte de l’estimulació amb Matrigel, de la relació amb l’expressió del Factor de Creixement de l’Endoteli Vascular (VEGF) i de l’efecte de la transfecció del cDNA del VEGF en sentit i antisentit sobre l’angiogènesi i el comportament tumorals. Estudi en melanomes humans i en línies de melanoma humà xenoempeltades a ratolins immunodeprimits, Barcelona, 2004. [www.tdx.cesca.es/TDX-0414105-093745/] 29. Nicola Luz, PhD Thesis: Untersuchung der Gefäßdichte bei metastasierten und nicht- metastasierten Magenkarzinomen. Techn. Hochsch., Diss., 2003--Aachen [sylvester.bth.rwth-aachen.de/.../03_185.pdf] 30. In BOOK: Textbook of Melanoma, Edd: John F. Thompson, Donald L. Morton, Bin B. R. Kroon, p146, Informa Health Care, 2004 http://books.google.bg/books?id=ZiQ0d59sG0cC&pg=PA146&lpg=PA146&dq=Vlaykova+T& source=web&ots=qmUEmOjrK8&sig=DL8TfGKlzwePVF826Gq6Sx4JN7o&hl=bg&sa=X&oi =book_result&resnum=8&ct=result 31. In BOOK: Pathology of Melanocytic Nevi and Malignant Melanoma, Second Eddition, Edd: Raymond L. Barnhill, Michael Piepkorn, Klaus J. Busam, p391, Springer, 2004 http://books.google.bg/books?id=Xzl- NL4HIrYC&pg=PA391&lpg=PA391&dq=Vlaykova+T&source=web&ots=1iz4qN4xJ6&sig=- Higo3dYd1Nit3HySB8yElKxoCQ&hl=bg&sa=X&oi=book_result&resnum=9&ct=result 32. In Book, VEGF and Cancer, Edd. Judith H. Harmey, p 52, Springer, 2004 http://books.google.bg/books?id=h7A74b_8x8cC&pg=PA53&lpg=PA53&dq=Vlaykova+T&so urce=web&ots=v7ds6E7dJe&sig=0LZT- YM9wJA4M3kUY1qDRZn5sSs&hl=bg&sa=X&oi=book_result&resnum=7&ct=result#PPA52, M1 33. In Book, The pigmentary system: physiology and pathophysiology, James J. Nordlund, Raymond E. Boissy, Vincent J. Hearing, William Oetting, Richard A. King, Jean-Paul Ortonne, 31 Wiley-Blackwell, 2006 http://books.google.bg/books?id=CtdwxA4NtnQC&pg=PA487&lpg=PA487&dq=Vlaykova+T &source=web&ots=AdL0PgDLT0&sig=5FWk2MSUGE26XVOSUjiaQQsVARM&hl=bg&sa= X&oi=book_result&resnum=4&ct=result

12. Цитирана статия Increased thymidylate synthase gene expression in metastatic melanoma VLAYKOVA T, JEKUNEN AP, KESOMAA M, et al. ONCOLOGY, 54 (2): 146-152 MAR-APR 1997 1. Hatse S, De Clercq E, Balzarini J Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation BIOCHEMICAL PHARMACOLOGY 58 (4): 539-555 AUG 15 1999 2. Ulrich, CM, Bigler, J, Velicer, CM, Greene, EA, Farin, FM, Potter, JD Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the Thymidylate synthase gene CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (IF-3,572), 1381-1385, 2000 3. IVANA GRIVICICH, ADRIANA BRONDANI DA ROCHA, ANDRÉA REGNER, DANIEL THOMPSEN PASSOS, KESS SMID, GUILHERME BLAUTH KAYSER, JOÃO ANTÔNIO PÊGAS HENRIQUES, GODEFRIDUS PETERS, GILBERTO SCHWARTSMANN, Effects of irinotecan/5-fluorouracil combination on thymidylate synthase and cell cycle in human colon carcinoma cell line Revista da AMRIGS, Porto Alegre, 50 (2): 139-144, abr.-jun. 2006 (http://www.amrigs.org.br/revista/50-2/ao05.pdf) 4. ENZYME CATALYZED THERAPEUTIC AGENTS SHEPARD, H., Michael, GROZIAK, Michael, P. ( TECHNICAL FIELD ) The present invention relates to the field of drug discovery and specifically, the design of prodrugs which are substrates for an intracellular enzyme critical to resistance to therapeutics in pathological cells and converted to a cell ... Patent record available from the European Patent Office, 2000

13. Цитирана статия Immunohistochemically detectable Bcl-2 expression in metastatic melanoma: Association with survival and treatment response VLAYKOVA T, TALVE L, HAHKA-KEMPPINEN M, et al. ONCOLOGY, 62 (3): 259-268 2002 1. Baxevanis, CN; Perez, SA; Papamichail, M. Cancer immunotherapy. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES 46 (4): 167-189 2009. 2. Rothberg, BEG; Bracken, MB; Rimm, DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. JOURNAL OF THE NATIONAL CANCER INSTITUTE 101 (7): 452-474 APR 1 2009 3. Zbytek, B., Carlson, J.A., Granese, J., Ross, J., Mihm Jr., M., Slominski, A. Current concepts of metastasis in melanoma. Expert Review of Dermatology 3 (5), pp. 569-585, 2008. 4. Begley J, Ribas A, Targeted Therapies to Improve Tumor Immunotherapy, Clinical Cancer Research 14, 4385-4391, 2008. doi: 10.1158/1078-0432.CCR-07-4804. 5. Ortega, A; Carretero, J; Obrador, E; Estrela, JM. Tumoricidal activity of endothelium-derived NO and the survival of metastatic cells with high GSH and Bcl-2 levels. NITRIC OXIDE- BIOLOGY AND CHEMISTRY 19 (2): 107-114 SEP 2008 32 6. Koudryavtsev, D.V., Koudryavtseva, G.T., Mardynsky, Yu.S., Adjuvant chemotherapy as a component of complex treatment for skin melanoma, Voprosy Onkologii 54 (2), pp. 170-177, 2008 7. Torikai, H; Akatsuka, Y; Yatabe, Y; Morishima, Y; Kodera, Y; Kuzushima, K; Takahashi, T. Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation. INTERNATIONAL JOURNAL OF HEMATOLOGY 87 (5): 467-473 JUN 2008 8. Mena, S; Benlloch, M; Ortega, A; Carretero, J; Obrador, E; Asensi, M; Petschen, I; Brown, BD; Estrela, JM. Bcl-2 and glutathione depletion sensitizes B16 melanoma to combination therapy and eliminates metastatic disease. CLINICAL CANCER RESEARCH 13 (9): 2658-2666 MAY 1 2007 9. Lana Y. Schumacher1,* and Antoni Ribas. Overcoming tumor resistance to immunotherapy. Review Article. Cancer Therapy Vol 4, 13-26, 2006. http://www.cancer-therapy.org/CT4A/HTML/02.%20Schumacher%20&%20Ribas,%2013- 26.html 10. Chin L, Garraway LA, Fisher DE Malignant melanoma: genetics and therapeutics in the genomic era GENES & DEVELOPMENT 20 (16): 2149-2182 AUG 15 2006 11. Bosserhoff AK Novel biomarkers in malignant melanoma CLINICA CHIMICA ACTA 367 (1- 2): 28-35 MAY 2006 12. Staibano, S., Pepe, S., Muzio, L.L., Somma, P., Mascolo, M., Argenziano, G., Scalvenzi, M., (...), De Rosa, G..Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region HUMAN PATHOLOGY 36 (7): 724-731 JUL 2005 13. Linette, G.P., Carlson, J.A., Slominski, A., Mihm Jr., M.C., Ross, J.S. Biomarkers in melanoma: Stage III and IV disease EXPERT REVIEW OF MOLECULAR DIAGNOSTICS 5 (1): 65-74 JAN 2005 14. Carlson, J.A., Ross, J.S., Slominski, A., Linette, G., Mysliborski, J., Hill, J., Mihm Jr., M. Molecular diagnostics in melanoma JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 52 (5): 743-775 MAY 2005 15. Penmatcha, S., Rovinsky, S.A., Cockerell, C.J., Hsu, M.-Y. Advances in prognostication of cutaneous malignant melanoma Advances in Dermatology 20, pp. 323-343, 2004 16. Bilalovic, N., Sandstad, B., Golouh, R., Nesland, J.M., Selak, I., Torlakovic, E.E. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression MODERN PATHOLOGY 17 (10): 1251-1258 OCT 2004 17. Lumb PD, Suvarna SK Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease HISTOPATHOLOGY 44 (4): 345-352 APR 2004 18. Kallio, J.P., Hirvikoski, P., Helin, H., Kellokumpu-Lehtinen, P., Luukkaala, T., Tammela, T.L.J., Martikainen, P.M. Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma BRITISH JOURNAL OF CANCER 89 (7): 1266-1269 OCT 6 2003 19. Bush JA, Li G The role of Bcl-2 family members in the progression of cutaneous melanoma CLINICAL & EXPERIMENTAL METASTASIS 20 (6): 531-539 2003 20. Shangary S, Johnson DE Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family LEUKEMIA 17 (8): 1470-1481 AUG 2003 21. Hersey P, Zhang XD Overcoming resistance of cancer cells to apoptosis JOURNAL OF CELLULAR PHYSIOLOGY 196 (1): 9-18 JUL 2003 22. Hakansson A, Gustafsson B, Abdiu A, et al. Bcl-2 expression in metastatic malignant melanoma. Importance for the therapeutic efficacy of biochemotherapy CANCER IMMUNOLOGY IMMUNOTHERAPY 52 (4): 249-254 APR 2003 23. López-Muñiz, A., Triviño, A., García-Fernández, C., Gil Verona, J.A., Herrero Zapatero, A. Quantitative analysis of ki67 expression in benign and malignant melanocytic lesions | [Análisis cuantitativo de la expresión ki67 en lesiones melanocíticas benignas y malignas] . 33 Oncologia 26 (2), pp. 49-54, 2003 24. Johanna Nikkola Integrins and MMPs as prognostic factors in metastatic melanoma, PhD thesis book, Turku University, 2004 Dept. Oncology and Radiotherapy, Turku University Central Hospital, University of Turku 25. Jukka Kalio, PhD Thesis: Prognostic factors in Renal cell carcinoma. Tampere, 2004 26. Suvi Ilmonen. PhD Thesis: PROGNOSTIC FACTORS OF PRIMARY CUTANEOUS MELANOMA, Helsinki 2005 27. In BOOK: Textbook of Melanoma, Edd: John F. Thompson, Donald L. Morton, Bin B. R. Kroon, p146 http://books.google.bg/books?id=ZiQ0d59sG0cC&pg=PA146&lpg=PA146&dq=Vlaykova+T& source=web&ots=qmUEmOjrK8&sig=DL8TfGKlzwePVF826Gq6Sx4JN7o&hl=bg&sa=X&oi =book_result&resnum=8&ct=result

14. Цитирана статия MIB-1 immunoreactivity correlates with blood vessel density and survival in disseminated malignant melanoma VLAYKOVA T, TALVE L, HAHKA-KEMPPINEN M, et al. ONCOLOGY, 57 (3): 242-252 1999

1. Wohlfart, S., Bernreuther, C., Khalansky, A.S., Theisen, A., Weissenberger, J., Gelperina, S., Glatzel, M., Kreuter, J. Increased numbers of injections of doxorubicin bound to nanoparticles lead to enhanced efficacy against rat glioblastoma 101/8. Journal of Nanoneuroscience, 1 (2) pp. 144-151. 2010

2. Rothberg, BEG; Bracken, MB; Rimm, DL. Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis. JOURNAL OF THE NATIONAL CANCER INSTITUTE 101 (7): 452-474 APR 1 2009 1* 2 3 4 3. Rishab K. Gupta , Alistair J. Cochran , Eddy C. Hsueh , Steven D. Trocha , Donald L. Morton, NACB: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic Melanoma (Section 3L) 1 National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Malignant Melanoma,1-42 2008 4. Donskov F, Marcussen N, Hokland M, et al.In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma BRITISH JOURNAL OF CANCER 90 (3): 626-631 FEB 9 2004 5. Laing JHE, Wilson GD, Martindale CA Proliferation rates in human malignant melanoma: relationship to clinicopathological features and outcome MELANOMA RESEARCH 13 (3): 271-277 JUN 2003 6. Arashiro K The tumor vasculature in cutaneous malignant melanoma: Scanning electron microscopy of corrosion casts PLASTIC AND RECONSTRUCTIVE SURGERY 110 (2): 717- 718 AUG 2002 7. Gulubova M, Vodenicharov A Structural examination of tryptase-, and VIP-positive mast cells in the commons bile duct of patients with lithiasis ACTA HISTOCHEMICA 103 (4): 437- 452 OCT 2001 8. Kamarashev J, Burg G, Kempf W, Dummer R. Prognoseevaluation mittels Immunhistologie Immunohistology for Prognostic Evaluation Akt Dermatol 2002; 28: 314-318 9. Jari M. Karjalainen, Transcription Factors and Other Dysregulated Proteins in Melanoma Prognosis [abstract] Current Oncology Reports 2001, 3:368-375 http://www.current- reports.com/article.cfm?PubID=OR03-4-2- 06&KeyWords=&Type=Abstract&CFID=15479738&CFTOKEN=71610519 10. Johanna Nikkola Integrins and MMPs as prognostic factors in metastatic melanoma, PhD thesis book, Turku University, 2004 Dept. Oncology and Radiotherapy, Turku University Central Hospital, University of Turku 34 11. In BOOK: Lever's Histopathology of the Skin, Edds. Walter Frederick Lever, David E. Elder, Rosalie Elenitsas, Bernett L. Johnson, George, p802, 12. In BOOK: Textbook of Melanoma, Edd: John F. Thompson, Donald L. Morton, Bin B. R. Kroon, p146, Informa Health Care, 2004 http://books.google.bg/books?id=ZiQ0d59sG0cC&pg=PA146&lpg=PA146&dq=Vlaykova+T& source=web&ots=qmUEmOjrK8&sig=DL8TfGKlzwePVF826Gq6Sx4JN7o&hl=bg&sa=X&oi =book_result&resnum=8&ct=result 13. In BOOK: Tumor Markers, Physiology, Pathobiology, Thechnology, and Clinical Applications, Edd: Eleftherios P. Diamandis, Herbert A. Fritscher, Hans Lilja, Daniel W. Chan, Morton K. Schwartz, AACCPress, p372, 2002 http://books.google.bg/books?id=qwJHDfXMozUC&pg=RA1-PA372&lpg=RA1- PA372&dq=Vlaykova+T&source=web&ots=BSGvyP5lVC&sig=EFuewZcTH8GSuj47zEA_Fc DFLss&hl=bg&sa=X&oi=book_result&resnum=10&ct=result#PRA1-PA373,M1

15. Цитирана статия

Evaluation of oxidative stress in patients with cancer HRISTOZOV D, GADJEVA V, VLAYKOVA T, DIMITROV G ARCH PHYSIOL BIOCHEM, 109: 331 2001

1. Patel, J.B., Shah, F.D., Shukla, S.N., Shah, P.M., Patel, P.S. Role of nitric oxide and antioxidant enzymes in the pathogenesis of oral cancer. Journal of Cancer Research and Therapeutics, 5 (4) pp. 247-253. 2009. 2. Salzman, R., Pácal, L., Tomandl, J., Kaňková, K., Tóthová, E., Gál, B., Kostřica, R., Salzman, P. Elevated malondialdehyde correlates with the extent of primary tumor and predicts poor prognosis of oropharyngeal cancer. Anticancer Research, 29 (10) pp. 4227-4231.2009 3. Zorba, YO; Yildiz, M; Yildirim, A; Gursan, N; Ercans, E. Reactions of connective tissue to self- etching/priming dentin bonding systems: oxidative stress, tumor necrosis factor a expression, and tissue reactions. JOURNAL OF DENTAL SCIENCES 4 (3): 136-148 SEP 2009. 4. Milasiene V, Surinenaite B, Prasmickiene G, Didziapetriene J, Stratilatovas E. Parameters of immune and antioxidative systems can be considered as surgical stress markers for gastric cancer patients. Internatinal Journal of Medicine and Medical Sciences Vol. 1(6), pp. 241-247, June, 2009 5. Mahmood, I.H., Abdullah, K.S., Abdullah, M.S. Total antioxidant status in women with breast cancer. Pakistan Journal of Medical Sciences, 25 (4) pp. 609-612., 2009 6. Khan, T.H., Sultana, S. . Antioxidant and hepatoprotective potential of Aegle marmelos Correa. against CCl4-induced oxidative stress and early tumor events. Journal of Enzyme Inhibition and Medicinal Chemistry 24 (2), pp. 320-327, 2009. 7. Mahdavi, R; Faramarzi, E; Seyedrezazadeh, E; Mohammad-zadeh, M; Pourmoghaddam, M. Evaluation of Oxidative Stress, Antioxidant Status and Serum Vitamin C Levels in Cancer Patients. BIOLOGICAL TRACE ELEMENT RESEARCH 130 (3): 1-6 JUL 2009. 8. Ajith, T.A., Anu, V., Riji, T. Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice. Journal of Experimental Therapeutics and Oncology, 7 (4) pp. 291-298. 2008. 9. Rajneesh, C.P., Manimaran, A., Sasikala, K.R., Adaikappan, P. Lipid peroxidation and antioxidant status in patients with breast cancer. Singapore Medical Journal 49 (8), pp. 640- 643, 2008 10. Szczubiał, M., Kankofer, M., Albera, E., Łopuszyński, W., Da browski, R. Oxidative/antioxidative status of blood plasma in bitches with mammary gland tumours Bulletin of the Veterinary Institute in Pulawy 52 (2), pp. 255-259, 2008 35 11. Das, S; Mahapatra, SK; Gautam, N; Das, A; Roy, S. Oxidative stress in lymphocytes, neutrophils, and serum of oral cavity cancer patients: modulatory array of L-glutamite. SUPPORTIVE CARE IN CANCER 15 (12): 1399-1405 DEC 2007 12. Rasheed, MH; Beevi, SS; Rajaraman, R; Bose, SJC. Alleviation of oxidative and nitrosative stress following curative resection in patient with oral cavity cancer. JOURNAL OF SURGICAL ONCOLOGY 96 (3): 194-199 SEP 1 2007 13. Mikirova, N.A., Jackson, J.A., Riordan, N.H. The effect of high dose IV vitamin C on plasma antioxidant capacity and level of oxidative stress in cancer patients and healthy subjects. Journal of Orthomolecular Medicine 22 (3), pp. 153-160, 2007 14. Salzman, R., Kostřica, R., Pácal, L., Tomandl, J., Kaňková, K., Horáková, Z. Role of superoxide dismutase in spinocellular carcinoma of head and neck - A pilot study | [Role superoxiddismutázy u spinocelulárních karcinomů hlavy a krku - Pilotní výsledky] Otorinolaryngologie a Foniatrie 56 (1), pp. 24-30, 2007 15. Salzman, R., Tomandl, J., Pácal, L., Kaňková, K., Horáková, Z., Kost řica, R. Oxidative stress and carcinogenesis - Theoretical introduction | [Oxidativní stres a karcinogeneze - Teoretický úvod], Otorinolaryngologie a Foniatrie 56 (1), pp. 39-44 2007 16. Czeczot, H., Ścibior, D., Skrzycki, M., Podsiad, M. Level of lipid peroxidation in blood serum of patients with pancreatitis and pancreatic cancer , Gastroenterologia Polska 14 (1), pp. 13-16, 2007 17. Ho JC, Chan-Yeung M, Ho SP, et al.Disturbance of systemic antioxidant profile in nonsmall cell lung carcinoma EUROPEAN RESPIRATORY JOURNAL Volume: 29 Issue: 2 Pages: 273-278 Published: 2007 18. Pejic S, Kasapovic J, Todorovic A, et al.Lipid peroxidation and antioxidant status in blood of patients with uterine myoma, endometrial polypus, hyperplastic and malignant endometrium BIOLOGICAL RESEARCH Volume: 39 Issue: 4 Pages: 619-629 Published: 2006 19. Pajović, S.B., Saičić, Z.S., Pejić, S., Kasapović, J., Stojiljković, V., Kanazir, D.T. Antioxidative biomarkers and cancerogenesis Jugoslovenska Medicinska Biohemija 25 (4), pp. 397-402, 2006 20. Ramprasath VR, Kumar BS, Shanthi P, et al.Therapeutic efficacy of Kalpaamruthaa on lipid peroxidation and antioxidant status in experimental mammary carcinoma in rats JOURNAL OF HEALTH SCIENCE 52 (6): 748-757 DEC 2006 21. Aghvami T, Djalali M, Keshavarz A, et al.Plasma level of antioxidant vitamins and lipid peroxidation in breast cancer patients IRANIAN JOURNAL OF PUBLIC HEALTH 35 (1): 42- 47 2006 22. Ozensoy O, Kockar F, Arslan O, et al.An evaluation of cytosolic erythrocyte carbonic anhydrase and catalase in carcinoma patients: An elevation of carbonic anhydrase activity CLINICAL BIOCHEMISTRY 39 (8): 804-809 AUG 2006 23. Maldonado PA, Negrini LA, Kaizer RR, et al.Oxidative status in patients submitted to conization and radiation treatments for uterine cervix neoplasia CLINICA CHIMICA ACTA 366 (1-2): 174-178 APR 2006 24. Ajith TA, Harikumar KB, Thasna H, et al.Proapoptotic and antitumor activities of the HMG- CoA reductase inhibitor, lovastatin, against Dalton's Lymphoma Ascites tumor in mice CLINICA CHIMICA ACTA 366 (1-2): 322-328 APR 2006 25. Didþiapetrienë Janina, Kazbarienë Birutë, Prasmickienë Graþina, Krikðtaponienë Aurelija, Surinënaitë Birutë. The immune and antioxidative state of women with respect to cervical cancer stage ACTA MEDICA LITUANICA. 2005. VOLUME 12 No. 3. P. 65–70 26. Gonenc A, Tokgoz D, Aslan S, et al.Oxidative stress in relation to lipid profiles in different stages of breast cancer INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS 42 (3): 190-194 JUN 2005 27. Erker L, Schubert R, Yakushiji H, et al.Cancer chemoprevention by the antioxidant tempol acts partially via the p53 tumor suppressor HUMAN MOLECULAR GENETICS 14 (12): 1699- 1708 JUN 15 2005 36 28. Mainous AG, Wells BJ, Koopman RJ, et al.Iron, lipids, and risk of cancer in the Framingham Offspring cohort AMERICAN JOURNAL OF EPIDEMIOLOGY 161 (12): 1115-1122 JUN 15 2005 29. Wells BJ, Mainous AG 3rd, Everett CJ, Gill JM. Iron, cholesterol, and the risk of cancer in an 18-year cohort. Asian Pac J Cancer Prev. 2005 Oct-Dec;6(4):505-9. 30. Tas F, Hansel H, Belce A, et al.Oxidative stress in breast cancer MEDICAL ONCOLOGY 22 (1): 11-15 2005 31. Khanna R, Thapa PB, Khanna HD, Khanna S, Khanna AK, Shukla HS. Lipid peroxidation and antioxidant enzyme status in oral carcinoma patients. Kathmandu Univ Med J (KUMJ). 2005 Oct-Dec;3(4):334-9. 32. Szczubiał M, Kankofer M, Łopuszyński W, Dabrowski R, Lipko J. Oxidative stress parameters in bitches with mammary gland tumours. J Vet Med A Physiol Pathol Clin Med. 2004 Sep- Oct;51(7-8):336-40. 33. Kalpana C, Menon VP Inhibition of nicotine-induced toxicity by curcumin and curcumin analog: A comparative study JOURNAL OF MEDICINAL FOOD 7 (4): 467-471 WIN 2004 34. Szczubial M, Kankofer M, Lopuszynski W, et al.Oxidative stress parameters in bitches with mammary gland tumours JOURNAL OF VETERINARY MEDICINE SERIES A- PHYSIOLOGY PATHOLOGY CLINICAL MEDICINE 51 (7-8): 336-340 SEP 2004 35. Beevi SSS, Rasheed AMH, Geetha A Evaluation of oxidative stress and nitric oxide levels in patients with oral cavity cancer JAPANESE JOURNAL OF CLINICAL ONCOLOGY 34 (7): 379-385 JUL 2004 36. Vida Milasiene,Graþina Prasmickiene,Violeta Norkiene,Renata Jonusauskaite,Eugenijus Stratilatovas,Janina Didziapetriene. T-lymphocyte subsets and lipid peroxidation in relation to survival among advanced gastric cancer patients. ACTA MEDICA LITUANICA. 2004. VOLUME 11. No. 4. P. 19–23 37. Trueba GP, Sanchez GM, Giuliani A Oxygen free radical and antioxidant defense mechanism in cancer FRONTIERS IN BIOSCIENCE 9: 2029-2044 Suppl. S SEP 1 2004 38. Yildiz M., Taysi S., Yildiz A., Bakan N., Akcay F., Kuskay S. Effect of composite resin filling material implantation into connective tissue of rabbits on oxidative stress in erythrocyte. Pain Clinic 2004, 16(3):323-328. 39. Yildiz, M., Akyuz, M., Yildiz, A., Bakan, E. The effect of ormocer filling material implanted into rabbit connective tissue on erythrocytes oxidative stress European Journal of Inflammation 2 (2), pp. 85-90, 2004 40. Liu XJ, Zhao J, Zheng RL DNA damage of tumor-associated lymphocytes and total antioxidant capacity in cancerous patients MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 539 (1-2): 1-8 AUG 5 2003 41. Bhuvaneswari V, Mohan KVPC, Nagini S, et al.Sequential changes in the cellular redox state during 7,12-dimethylbenz[a]anthracene-induced carcinogenesis in the hamster buccal pouch TOXICOLOGY MECHANISMS AND METHODS 13 (3): 227-234 JUL-SEP 2003 42. Birute Kazbariene, Grazina Prasmickiene, Aurelija Krikstaponiene, Dalia Sukeliene, Arvydas Burneckis, Janina Didziapetriene [Changes in the parameters of immune and antioxidant systems in patients with cervical cancer]. Medicina (Kaunas). 2004 ;40 (12):1158-64 43. Subapriya R, Kumaraguruparan R, Ramachandran CR, Nagini S. Oxidant-antioxidant status in patients with oral squamous cell carcinomas at different intraoral sites. Clin Biochem. 2002 Sep;35(6):489-93. 44. Aktan B, Taysi S, Gumustekin K, et al.Evaluation of oxidative stress in erythrocytes of guinea pigs with experimental otitis media and effusion ANNALS OF CLINICAL AND LABORATORY SCIENCE 33 (2): 232-236 SPR 2003 45. Subapriya R, Kumaraguruparan R, Nagini S, et al.Oxidant-antioxidant status in oral precancer and oral cancer patients TOXICOLOGY MECHANISMS AND METHODS 13 (1): 77-81 JAN- MAR 2003 37 46. Kumaraguruparan R, Subapriya R, Viswanathan P, et al.Tissue lipid peroxidation and antioxidant status in patients with adenocarcinoma of the breast CLINICA CHIMICA ACTA 325 (1-2): 165-170 NOV 2002 47. Милашене В., Прасмiцкене Г., Бурнецкiс А., Норкене Б. Корекцiя имунноi и антиоксидантноi систем органiзму при променевiй терапii хворих на рак прямоi кишки III стадii. (Correction of the immune and antioxidant system in patients with stage III rectal cancer during radiation therapy.) украiнський Радiologичний Журнал, 12:394-398, 2004 48. Мутафчиев К. Съдържание на манган в серум и урина на пациенти с язвена болест, пациенти с желязодефицитна анемия и на електрозаварчици на нелигирана стомана. Scientific conference with an international participation “Stara Zagora-2005”, 2-3 June, 2005, Stara Zagora, Book with reports, 2005; 4:160-164. 49. Popova M., Nikolova N. Effect of repeated treatment with Agriya 1050 combined with Gamma irradiation on some lambs blood parameters. Bul J Ecol Sci. Ecology and Future, 2005, v. IV, N1 50. Popova M., Popov Ch. Lipid peroxidation and activity of enzymes located into different cell compartments. Bul J Ecol Sci. Ecology and Future, 2005, v. IV, N2 51. Ho, Chung-man, PhD Thesis, Non-small cell lung cancer : from bench to bedside MD Ho Chung Man 1 ABSTRACT Lung cancer, predominantly non-small cell carcinoma, has been the major cancer killer worldwide including in Hong Kong. Ever since the discovery of cigarette smoking as the major aetiologic factor for lung cancer in 1950s, [sunzi.lib.hku.hk/hkuto/record/B39432592], 2007 52. DR. YILDIRAY DADÜK, PhD Thesis: MİDE KANSERİNDE TOTALSİALİK ASİT, GLUTATYON, MALONDİALDEHİT SEVİYELERİ ve BU PARAMETRELERİN BİRBİRİYLE ve KANSER EVRESİ İLE İLİŞKİSİNİN İNCELENMESİ, İSTANBUL-2006 53. In BOOK: Radicais Livres E a Resposta Celular Ao Estresse Oxidativo, Edds. Marian Salvador, Joao A.P. Henriques p99, 2004 http://books.google.bg/books?id=7- GGjE62SAwC&pg=PA99&lpg=PA99&dq=Vlaykova+T&source=web&ots=OIf6NyRg_Q&sig =jSDPCOFHgYFtIU9THRw4dClWFL0&hl=bg&sa=X&oi=book_result&resnum=1&ct=result# PPA99,M1

16. Цитирания на статия: Reactive oxygen species, antioxidant enzymes and human diseases. Review- I. GADJEVA, V., VLAJKOVA, T., POPOVA, E., ET AL. BULGARIAN MEDICINE 2000. VOL VIII, N5 PP.21-24

1. Jalel, A., Yassine, M., Hamdaoui, M.H. Oxidative stress in experimental vitiligo C57Bl/6 mice. Indian Journal of Dermatology, 54 (3) pp. 221-224. 2009 2. Димитрова В., Гсподинов Д., Йорданова И, Мутафчиев К., Съдържание на желязо, мед и цинк в плазмата на пациенти с псориазис вулгарис. Scientific conference with an international participation “Stara Zagora-2007”, 7 -8 June, 2007, Stara Zagora, 2007, Book with reports, 8:269-273. 3. V. V. UZUNOVA, A. N. TOLEKOVA, G. S. ILIEVA, , K. I. TRIFONOVA & A. P. LOGOFETOV, RENIN-ANGIOTENSIN SYSTEM AND LIPID PEROXIDATION, Bulgarian Journal of Veterinary Medicine (2005), 8, No 1, 69_75 4. E. Hristakieva, Vitiligo and other associated diseases, Trakia Journal of Sciences, Vol.1, No 3, pp 60-62, 2003 5. Страшимиров Д, Цачев К, Мутафчиев К. Съдържание на манган в някои лечебни растения и в техните водни извлеци. Scientific conference with an international participation “Stara Zagora-2005”, 2-3 June, 2005, Stara Zagora, Book with reports, 2005; 4:156-159 38 6. Мутафчиев К. Съдържание на манган в серум и урина на пациенти с язвена болест, пациенти с желязодефицитна анемия и на електрозаварчици на нелигирана стомана. Scientific conference with an international participation “Stara Zagora-2005”, 2-3 June, 2005, Stara Zagora, Book with reports, 2005; 4:160-164. 7. Попова М. Прекисно окисляване на липидите in vivo и in vitro при норма и патология. Животновъдни науки, 2005, XLII, 3 8. Popova M., Nikolova N. Effect of repeated treatment with Agriya 1050 combined with Gamma irradiation on some lambs blood parameters. Bul J Ecol Sci. Ecology and Future, 2005, v IV, N1 9. Попова М., Влияние на хранителни добавки върху кръвни показатели при пилета- бройлери. Животновъдни науки, 2005, XLII, 4

17. Цитирания на статия: Influence of chemotherapy on the antioxidant status in patients with various hematological diseases, KUCHUKOVA D, GADJEVA V, VLAYKOVA T, ET. AL., IMAB ANNUAL PROCEEDINGS (SCIENTIFIC PAPERS), 2001; 7(1):111-113.

1. Mileva M, Zlateva G. Comparing effect of low-intensity laser irradiation and vitamine E on oxidative damages in experimental model of diquat-induced cataract in rabbit. Trakia J Sci, 2005, 3(3):6-9 2. Delijska B., Mileva M. Циклофосфамид и оксидативен стрес. Актуална нефрология. 2005, том 5, бр 2(16)

18. Цитирания на статия:

Immunohistochemical assessment of fibronectin and tenascin and their integrin receptors alpha5beta1 and alpha9beta1 in gastric and colorectal cancers with lymph node and liver metastases, GULUBOVA M, VLAYKOVA T. ACTA HISTOCHEM. 2006;108(1):25-35(IF=0,656)

1. Lydolph, MC; Morgan-Fisher, M; Hoye, AM; Couchman, JR; Wewer, UM; Yoneda, A. Alpha 9 beta 1 Integrin in melanoma cells can signal different adhesion states for migration and anchorage. EXPERIMENTAL CELL RESEARCH 315 (19): 3312-3324 NOV 15 2009 2. Paschos, KA; Canovas, D; Bird, NC The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. CELLULAR SIGNALLING 21 (5): 665-674 MAY 2009 3. Kocher, H.M., Sandle, J., Mirza, T.A., Li, N.F., Hart, I.R. Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells. Gut, 58 (2) pp. 271-284.2009 4. Zagzag, D., Swindle, C.S., Cai, M., Zagzag, D., Prieto, A.L., et al. Gene: TNC – tenascin C, Wikigenes evolutionary knowledge, http://www.wikigenes.org/e/gene/e/3371.html 5. Zhang, A; Chen, G; Meng, L; Wang, QS; Hu, W; Xi, L; Gao, QL; Wang, SX; Zhou, JF; Xu, G; Meng, L; Ma, D. Antisense-snail transfer inhibits tumor metastasis by inducing E-cadherin expression. ANTICANCER RESEARCH 28 (2A): 621-628 MAR-APR 2008 6. Robertson, J.H., Iga, A.M., Sales, K.M., Winslet, M.C., Seifalian, A.M., Integrins: A method of early intervention in the treatment of colorectal liver metastases. CURRENT 39 PHARMACEUTICAL DESIGN Volume: 14 Issue: 3 Pages: 296-305 Published: JAN 2008 7. Lundin, M; Nordling, S; Lundin, J; Haglund, C. Tenascin-C expression and its prognostic significance in colorectal cancer. ONCOLOGY 72 (5-6): 403-409 2007 8. Degl'Innocenti, DR; Castiglione, F; Buccoliero, AM; Bechi, P; Taddei, GL; Freschi, G; Taddei, A. Quantitative expression of the homeobox and integrin genes in human gastric carcinoma. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 20 (4): 621-629 OCT 2007 9. Gradilone, A; Gazzaniga, P; Cigna, E; Vasaturo, F; Vincenzi, B; Gandini, O; Silvestri, I; Ribuffo, D; Scarpa, S; Scuderi, N; Agliano, AM. Fibronectin and laminin expression in sentinel lymph nodes of patients with malignant melanoma. BRITISH JOURNAL OF DERMATOLOGY 157 (2): 398-401 AUG 2007 10. Andrea Brunner and Alexandar Tzankov, The Role of Structural Extracellular Matrix Proteins in Urothelial Bladder Cancer (Review). Biomarker Insights 2007:2 418–427 11. http://en.wikipedia.org/wiki/itga9, - ITGA9, From Wikipedia, the free encyclopedia 12. http://www.genecards.org/cgi-bin/carddisp.pl?gene=Itga9, in GeneCards, ITGA9 Gene, integrin, alpha 9, , PubMed articles for ITGA9 gene

19. Цитирания на статия: Morphological and Immunocytochemical Investigations on Mast Cells in Porcine Ureter. VODENICHAROV A, LEISER R, GULUBOVA M, VLAYKOVA T. ANAT HISTOL EMBRYOL. 2005;34(6):343-349. (IF-=0,372, 2005) 1. Nemolato, S., Cabras, T., Fanari, M.U., Cau, F., Fraschini, M., Manconi, B., Messana, I., Castagnola, M., Faa, G. Thymosin beta 4 expression in normal skin, colon mucosa and in tumor infiltrating mast cells. European Journal of Histochemistry, 54 (1) pp. 14-17. 2010 2. Oberritter, Z., Rolle, U., Juhasz, Z., Cserni, T., Puri, P. Altered expression of c-kit-positive cells in the ureterovesical junction after surgically created vesicoureteral reflux. Pediatric Surgery International 25 (12), pp. 1103-1107, 2009. 3. Pena, G.A.C., Farina, G.I.G., Uribe, G.O., Tovar, C.G.G., Sanchez, T.A.C. Distribution of mast cells in the respiratory tract of the pig at three stages of development. Journal of Animal and Veterinary Advances, 8 (11) pp. 2241-2246. 2009 4. Meuser-Batista, M., Correa, J.R., Soares, M.J., Henriques-Pons, A. Isolation of cardiac mast cells in experimental Trypanosoma cruzi infection , Tissue and Cell 40 (5), pp. 309-316, 2008 5. Metzger, R; Rolle, U; Fiegel, HC; Frankel, FE; Muenstedt, K; Till, H C-kit receptor in the human vas deferens: distinction of mast cells, interstitial cells and interepithelial cells. REPRODUCTION 135 (3): 377-384 MAR 2008 6. Metzger, R; Neugebauer, A; Rolle, U; Bohlig, L; Till, H C-Kit receptor (CD117) in the porcine urinary tract. PEDIATRIC SURGERY INTERNATIONAL 24 (1): 67-76 JAN 2008 7. Simone Krebs, PhD thesis, Untersuchung zur alter- und zyklusabhängigen funktionellen Morphologie der porzinen Zervix Leipzig, Univ., Diss., 2007, [dol.dl.uni-leipzig.de/.../Word_Dissertation1m.pdf]

20. Цитирания на статия: Ile(105)Val GSTP1 polymorphism and susceptibility to colorectal carcinoma in Bulgarian population VLAYKOVA T, MITEVA L, GULUBOVA M, STANILOVA S INTERNATIONAL JOURNAL OF COLORECTAL DISEASE Volume: 22, Issue: 10, Pages: 1209-1215, Published: OCT 2007 40

1. Economopoulos KP, Sergentanis TN. GSTM1, GSTT1, GSTP1, GSTA1 and colorectal cancer risk: A comprehensive meta-analysis. European Journal of Cancer, 46 (9) pp. 1617-1631. 2010 2. Xu, X.-X., Chang, W.-J., Hou, J.-G., Xu, D.-F., Cui, X.-G., Zhai, Y.-J., Wang, G.-P., Zhang, H.- W., Cao, G.-W. Relationship of GSTP1, RASSF1A polymorphisms and environmental agent with susceptibility to prostate cancer: A case-control study. Academic Journal of Second Military Medical University, 31 (1) pp. 12-17. 2010 3. Gao, Y., Pan, X., Su, T., Mo, Z., Cao, Y., Gao, F. Glutathione S-transferase P1 Ile105Val polymorphism and colorectal cancer risk: A meta-analysis and HuGE review. European Journal of Cancer, 45 (18) pp. 3303-3314.2009 4. Colorectal Disease; Reports outline colorectal disease study findings from T. Vlaykova and colleagues CLINICAL ONCOLOGY WEEK. ATLANTA: Nov 5, 2007. pg. 155 5. Genetics & Genomics; Studies from T. Vlaykova et al in the area of genetics & genomics described GENOMICS & GENETICS WEEKLY. ATLANTA: Feb 1, 2008. pg. 186 6. Genetics & Genomics; Study findings from T. Vlaykova et al provide new insights into genetics & genomics GENOMICS & GENETICS WEEKLY. ATLANTA: Mar 7, 2008. pg. 135 (http://www.newsrx.com/newsletters/Cancer-Weekly/2008-03-04/1103042008477CW.html) 7. Reports outline colorectal disease study findings from T. Vlaykova and colleagues, Genetics & Environmental Health Week (2007-11-07), http://www.newsrx.com/newsletters/Genetics-and- Environmental-Health-Week/2007-11-07/5111072007150GH.html 8. Genomics and Health Weekly Update Human Genome Epidemiology (HuGE) Articles, April 5, 2007, Volume 18, No. 14, http://www.cdc.gov/genomics/hugenet/literature/2007/Hapr05.htm 9. Reports outline colorectal disease study findings from T. Vlaykova and colleagues, Gastroenterology Week (2007-11-05) 10. Койчев А., Илиева В., Димов Д., Пракова Г. Етиологична и клинична характеристика на пневмонии, придобити в обществото при болни хоспитализирани в „МБАЛ-Стара Загора” ЕАД за период 2005-2007”, Международна научна конференция, СУБ-Стара Загора, 5-6 юни, 2008, Сборник доклади (Електронна версия-CD). 11. Саръева Р. Изследване на полиморфни варианти в гени за ксенобиотик метаболизиращи ензими и гликопротеин –Р: асоциация с Балканска Ендемична Нефропатия и с отговор към лекарствена терапия с Аценокумарол. Дисертационен труд за степен „Доктор, 2008

21. Цитирания на статия: Adhesion molecules in chronic ulcerative colitis Gulubova M.V., Manolova I.M., Vlaykova T.I., Prodanova M., Jovchev J.P. (2007) International Journal of Colorectal Disease, 22 (6), pp. 581-589.

1. Dagia, N.M., Agarwal, G., Kamath, D.V., Chetrapal-Kunwar, A., Gupte, R.D., Jadhav, M.G., Dadarkar, S.S., Trivedi, J., Kulkarni-Almeida, A.A., Kharas, F., Fonseca, L.C., Kumar, S., Bhonde, M.R. A preferential p110α/γ PI3K inhibitor attenuates experimental inflammation by suppressing the production of proinflammatory mediators in a NF-κB-dependent manner. American Journal of Physiology - Cell Physiology, 298 (4) pp. C929-C941., 2010. 2. Yoshizaki, A; Nakayama, T; Naito, S; Sekine, I. Expression Patterns of Angiopoietin-1,-2, and Tie-2 Receptor in Ulcerative Colitis Support Involvement of the Angiopoietin/Tie Pathway in the Progression of Ulcerative Colitis. DIGESTIVE DISEASES AND SCIENCES 54 (10): 2094-2099 OCT 2009. 3. Chu, Z.-X., Qin, H.-L. Progress of gut associated lymphocyte homing in inflammatory bowel disease. World Chinese Journal of Digestology, 17 (7) pp. 687-693, 2009 41 4. Roifman, I., Sun, Y.C., Fedwick, J.P., Panaccione, R., Buret, A.G., Liu, H., Rostom, A., Anderson, T.J., Beck, P.L. Evidence of Endothelial Dysfunction in Patients With Inflammatory Bowel Diseas. Clinical Gastroenterology and Hepatology, 7 (2) pp. 175-182.2009 5. Mirbagheri, SA; Nezami, BG; Assa, S; Hajimahmoodi, M. Rectal administration of d-alpha tocopherol for active ulcerative colitis: A preliminary report. WORLD JOURNAL OF GASTROENTEROLOGY 14 (39): 5990-5995 OCT 21 2008. 6. Shi, H.-X., Ren, J.-L., Dong, W.-G. Advances in studies on relation between inflammatory bowel disease and immunity World Chinese Journal of Digestology 16 (4), pp. 399-405, 2008

22. Цитирания на статия: Effect of feeding Lactina® probiotic on performance, some blood parameters and caecal microflora of mule ducklings Djouvinov, D., S. Boicheva, T. Simeonova and T. Vlaikova 2005.. Trakia J. Sci., 3: 22-28. 1. Khaksar V., Golian A., Kermanshahi H. Movesseghaind AR., Jamshidi A. Effect of Prebiotic Fermacto on Gut Development and Performance of Broiler Chicen ed Diet Low in Digestible Amino Acids. Journal of Animal and Veterinary Advances, 7(3): 251-257, 2008. 2. Rangasamy Mathivanan+ and Kaliappan Kalaiarasi,. . Panchagavya and Andrographis paniculata as Alternatives to Antibiotic Growth Promoters on HAEMATOLOGICAL, SERUM BIOCHEMICAL PARAMETERS AND IMMUNE STATUS OF BROILERS. The Journal of Poultry Science, 44: 198-204-2007. 3. R. Mathivanan, S.C. Edwin, R. Amutha and K. Viswanathan. PANCHAGAVYA AND ANDROGRAPHIS PANICULATA AS ALTERNATIVES TO ANTIBIOTIC GROWTH PROMOTER ON BROILER PRODUCTION AND CARCASS CHARACTERISTICS International Journal of Poultry Science 5 (12): 1144-1150, 2006 4. Chafai Sihem. EFFECT DE L’ADDITION DES PROBIOTIUES DANS LES REGIMES ALIMENTAIRES SUR LES PERFORMANCES ZOOTECHNIQUES DU POULET DE CHAIR. Universite El-Hadj Lakhdar-Batna, Faculte des Sciences, Dept. Veterinaire, PhD Thesis, 2006, Books : 5. Yuan Kun Lee,Seppo Salminen. WileyHandbook of Probiotics and Prebiotics, 2nd Edition, 2009

23. Цитирания на статия: Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer Gulubova M., Vlaykova T. (2007) J Gastroenterol Hepatol,

1. Folarin, AA; Konerding, MA; Timonen, J; Nagl, S; Pedley, RB. Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography. MICROVASCULAR RESEARCH 80 (1): 89-98 JUL 2010. 2. Wilk, M; Liszka, L; Palen, P; Gabriel, A; Laudariski, P. Intensity of angiogenesis and mast cell infiltration in cervical intraepithelial and invasive lesions - Are they correlated? PATHOLOGY RESEARCH AND PRACTICE 206 (4): 217-222 2010. 3. Zlobec, I; Lugli, A. Invasive front of colorectal cancer: Dynamic interface of pro-/anti-tumor factors. WORLD JOURNAL OF GASTROENTEROLOGY 15 (47): 5898-5906 DEC 21 2009. 4. Crivellato, E., Nico, B., Ribatti, D. Mast cell contribution to tumor angiogenesis: A clinical approach. European Cytokine Network 20 (4), pp. 197-206, 2009. 5. Maltby, S., Khazaie, K., McNagny, K.M. Mast cells in tumor growth: Angiogenesis, tissue remodelling and immune-modulation. Biochimica et Biophysica Acta - Reviews on Cancer 1796 (1), pp. 19-26, 2009 42 6. Rasheed, S., Harris, A.L., Tekkis, P.P., Turley, H., Silver, A., McDonald, P.J., Talbot, I.C., Glynne-Jones R, Northover JM, Guenther, T. Hypoxia-inducible factor-1α and -2α are expressed in most rectal cancers but only hypoxia-inducible factor-1α is associated with prognosis. British Journal of Cancer 100 (10), pp. 1666-1673, 2009. 7. Yoo, P.S., Sullivan, C.A.W., Kiang, S., Gao, W., Uchio, E.M., Chung, G.G., Cha, C.H. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: High expression of HuR predicts poor survival Annals of Surgical Oncology 16 (1), pp. 200-207, 2009 8. Rasheed, S., Harris, A.L., Tekkis, P.P., Turley, H., Silver, A., McDonald, P.J., Talbot, I.C., Glynne-Jones, R., Northover, J.M.A., Guenther, T. Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancer. Pathology Research and Practice 205 (1), pp. 1-9, 2009 9. Kashiwase, Y., Inamura, H., Morioka,J., Igarashi, Y., Kawai-Kowase, K., Kurosawa, M. Quantitative analysis of mast cells in benign and malignant colonic lesions: Immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Allergologia et Immunopathologia 36 (5), pp. 271-276, 2008. 10. Hütter, G., Ganepola, S., Thiel, E., Hofmann, W.K. Inhibition of mast cell tryptase activity. A new therapeutic target against malignancy induced angiogenesis Bioscience Hypotheses 1 (4), pp. 213-217, 2008 11. Meuser-Batista, M., Correa, J.R., Soares, M.J., Henriques-Pons, A. Isolation of cardiac mast cells in experimental Trypanosoma cruzi infectionTissue and Cell 40 (5), pp. 309-316, 2008 12. Gaya, A., Daley, F., Taylor, N.J., Tozer, G., Qureshi, U., Padhani, A., Pedley, R.B., (...), Rustin, G. Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: An exploratory study British Journal of Cancer 99 (2), pp. 321-326, 2008 13. Sinnamon, M.J., Carter, K.J., Sims, L.P., Lafleur, B., Fingleton, B., Matrisian, L.M. A protective role of mast cells in intestinal tumorigenesis Carcinogenesis 29 (4), pp. 880-886, 2008

24. Цитирания на статия: Increased gene expression levels of collagen receptor integrins are associated with decreased survival parameters in patients with advanced melanoma Vuoristo M., Vihinen P., Vlaykova T., Nylund C., Heino J., Pyrhonen S. (2007) Melanoma Research, 17 (4), pp. 215-223. 1. Conway, C; Mitra, A; Jewell, R; Randerson-Moor, J; Lobo, S; Nsengimana, J; Edward, S; Sanders, DS; Cook, M; Powell, B; Boon, A; Elliott, F; de Kort, F; Knowles, MA; Bishop, DT; Newton-Bishop, J. Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival. CLINICAL CANCER RESEARCH 15 (22): 6939-6946 NOV 15 2009. 2. Tsukamoto, H; Kato, T; Enomoto, A; Nakamura, N; Shimono, Y; Jijiwa, M; Asai, N; Murakumo, Y; Shibata, K; Kikkawa, F; Takahashi, M. Expression of Ret finger protein correlates with outcomes in endometrial cancer. CANCER SCIENCE 100 (10): 1895-1901 OCT 2009. 3. Staniszewska, I; Walsh, EM; Rothman, VL; Gaathon, A; Tuszynski, GP; Calvete, JJ; Lazarovici, P; Marcinkiewicz, C. Effect of VP12 and viperistatin on inhibition of collagen receptors-dependent melanoma metastasis. CANCER BIOLOGY & THERAPY 8 (15): 1507- 1516 AUG 1 2009. 4. Meads, MB; Gatenby, RA; Dalton, WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. NATURE REVIEWS CANCER 9 (9): 665-A674 SEP 2009 43 5. Gramann, M; Wendler, O; Haeberle, L; Schick, B Prominent collagen type VI expression in juvenile angiofibromas. HISTOCHEMISTRY AND CELL BIOLOGY 131 (1): 155-164 JAN 2009 6. Shaikh, F.M., Seales, E.C., Clem, W.C., Hennessy, K.M., Zhuo, Y., Bellis, S.L. Tumor cell migration and invasion are regulated by expression of variant integrin glycoforms . Experimental Cell Research 314 (16), pp. 2941-2950, 2008

Патент: 7. NESHAT, Mehran, NOVEL PEPTIDES AND USES THEREOF The invention relates to a peptide of 8-50 amino acids comprising the sequenceof KAHKKEAD or KARKKHAD, or a cyclic peptide of 8-50 amino acids comprising thesequence of HKKR or RKKH. Also disclosed are methods of using the peptide for ... Patent record available from the World Intellectual Property Organization (WIPO), 2009

25. Цитирания на статия:

Sarov GM, Ilieva GS, Vlaykova TI, (2004) A case with unusual blood chemistry parameters following a glucose tolerance test and stress. Bulg J Vet Medicine 7(4): 235-238, 2004 1. S. S. Dimitrova, I. Penchev Georgiev, I. N. Kanelov, Y. I. Iliev, S. I. Tanev & T. Mircheva Georgieva, Intravenous glucose tolerance test and glucose kinetic parameters IN RABBITS, Journal of Veterinary Medicine 11(3), 161-169, 2008 2. S. DIMITROVA & I. PENCHEV GEORGIEV. RELATIVE CONTRIBUTION OF DECREASED INSULIN SENSITIVITY TO DETERIORATION OF GLUCOSE HOMEOSTASIS. Bulgarian Journal of Veterinary Medicine 10(4), 205-222, 2007 3. I. Penchev GEORGIEV, I. N. KANELOV, S. S. DIMITROVA, Y. I. ILIEV, S. I. TANEV, T. M. GEORGIEVA, B. L. BIVOLARSKI, e. G. VACHKOVA & I. I. GRIGOROV. AN EXPERIMENTAL MODEL FOR EVALUATION OF GLUCOSE TOLERANCE IN RABBIT. Bulgarian Journal of Veterinary Medicine 9(1), 27-35, 2006, 4. Иван Пенчев «Изследване на някои страни от физиологичното действие на системата соматотропин - инсулиноподобни растежни фактори и катехоламините в стомашно- чревния тракт на преживните животни” Докторат за доктор на науките, 2008.

26. Цитирания на статия:

Sarov G.M. & Vlaykova T.I. 2005. Changes in blood glucose, triglycerides and lipid peroxidation products in rabbits after hanging fixation. Bulgarian Journal of Veterinary Medicine. 8: 157-590. 1. Chellappan, D; Joseph, J; Shabi, MM; Krishnamoorthy, G; Ravindhran, D; Uthrapathy, S; Rajamanickam, VG; Dubey, GP. Psycho-emotional stress - A cause of coronary artery disease. ACTA SCIENTIAE VETERINARIAE 36 (2): 133-139 2008

27. Цитирания на статия:

Significance of tenascin-C, fibronectin, laminin, collagen IV, alpha 5 beta 1 and alpha 9 beta 1 integrins and fibrotic capsule formation around liver metastases originating from cancers of the digestive tract. Gulubova MV, Vlaykova TI, NEOPLASMA Volume: 53 Issue: 5 Pages: 372-383 Published: 2006 1. Angeli, F., Koumakis, G., Chen, M.-C., Kumar, S., Delinassios, J.G. Role of stromal fibroblasts in cancer: Promoting or impeding? Tumor Biology 30 (3), pp. 109-120, 2009. 2. Hirata, E; Arakawa, Y; Shirahata, M; Yamaguchi, M; Kishi, Y; Okada, T; Takahashi, JA; Matsuda, M; Hashimoto, N. Endogenous tenascin-C enhances glioblastoma invasion with 44 reactive change of surrounding brain tissue. CANCER SCIENCE 100 (8): 1451-1459 AUG 2009 3. Paschos KA, Canovas D, Bird NCSource: The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. CELLULAR SIGNALLING Volume: 21 Issue: 5 Pages: 665-674 Published: MAY 2009

28. Цитирания на статия:

Gulubova MV, Vlaykova TI. Mast cells in human bile duct obstruction . J Mol Histol. 35: 791-801. 2004

1. José García Domínguez - PhD thesis - RESPUESTA INFLAMATORIA ESPLÁCNICA EN LA COLESTASIS MICROQUIRÚRGICA EXPERIMENTAL, Facultad de Medicina, Departamento de Cirugía, Universidad Complutense de Madrid, Madrid, 2009

29. Цитирания на статия: Gulubova M.V., Yovchev Y., Vlaykova T., Hadjipetkov P., Prangova D.K., Popharitov A. Application of light microscopical and ultrastructural immunohistochemistry in the study of goblet cell carcinoid in the appendix (2008) World Journal of Surgical Oncology, 6, art. no. 15

1. Gramann, T., Matter, L., Pfofe, D., Flury, R., Jaeger, P. Metastazation into the seminal vesicles due to primary goblet cell carcinoid of the vermiform appendix. An unusual diagnostic procedure of a seminal vesicle tumor | [Samenblasenmetastase bei primärem Becherzellkarzinoid der Appendix vermiformis. Ein auergewöhnlicher Abklärungsgang eines Samenblasentumors]. Urologe - Ausgabe A 48 (11), pp. 1352-1355, 2009.

30. Цитирания на статия: Gulubova M, Vlaykova T, Manolova I, Hadjipetkov P, Popharitov A. Implication of adhesion molecules in inflammation of the common bile duct in patients with secondary cholangitis due to biliary obstruction. Hepatogastroenterology. 2008 May-Jun;55(84):836-41.

1. Melamed, R; Rosenne, E; Benish, M; Goldfarb, Y; Levi, B; Ben-Eliyahu, S. The Marginating-pulmonary Immune Compartment in Rats: Characteristics of Continuous Inflammation and Activated NK Cells. JOURNAL OF IMMUNOTHERAPY 33 (1): 16-29 JAN 2010

31. Цитирания на статия: Djouvinov D, Stefanov M, Boicheva S, Vlaikova T. Effect of diet formulation on basis of digestive amino acids and supplementation of probiotic on performance of broiler chicks. Trakia J Sci, 2005; 3 (1):61-69

1. Khaksar V, Golian A. Comparison of Ileal Digestible Versus Total Amino Acid Feed Formulation on Broiler performance. J Animal and Vet Advances, 8(7), 1308-1311, 2009. 2. Aida Kavazović, A. Gagić, Emina Rešidbegović, Fahira Alibegović-Zečić, T. Goletić, Ć. Crnkić, Aida Kustura, Almira Softić. UČINAK PROBIOTIKA NA PROIZVODNE REZULTATE BROJLERSKIH PILIĆA. STOČARSTVO 63:2009 (2) 49-55 ( 45 3. A. Paryad and M. Mahmoudi. Effect of different levels of supplemental yeast (Saccharomyces cerevisiae) on performance, blood constituents and carcass characteristics of broiler chicks. African Journal of Agricultural Research Vol. 3 (12), pp. 835-842, December, 2008. 4. . Chafai S, Ibrir F, Alloui N, Nouicer F. Effects of Pediococcus acidilactici Feed supplementation on Broiler chicken performances, Immunity and Health. . Proceedings of 16th European Symposium on Poultry Nutrition, August 26 - 30, 2007 Strasbourg , France 281-284.,

1. Цитирания на статия: Патенти по 1 1. NL6 tie receptor tyrosine kinase ligand homologue Fong, Sherman, Ferrara, Napoleone, Goddard, Audrey, Godowski, Paul J., Gurney, Austin L., Hillan, Kenneth, Williams, P. Mickey The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligand homologues NL2, NL3 and NL6 (FLS139), the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and ... Patent record available from the European Patent Office, 2009 2. Secreted and transmembrane polypeptides and nucleic acids endoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David, Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin [0001]The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the Patent record available from the European Patent Office, 2008 3. Compounds Adams, Jerry L., Bryan, Deborah L. The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred. Patent record available from the US Patent Office, 2008 4. Methods and compositions for screening for angiogenesis modulating compounds Ning, Zhang, Contag, Pamela Reilly, Purchio, Anthony F. The present invention relates to novel transcription control elements, including promoters, derived from angiogenesis-related genes, particularly the mouse VEGF gene, the mouse VEGFR-2 receptor gene, and the mouse Tie2 gene. Also disclosed are isolated ... Patent record available from the US Patent Office, 2007 5. Patent: (WO/2006/002854) TIE RECEPTOR AND TIE LIGAND MATERIALS AND METHODS FOR MODULATING FEMALE FERTILITY, http://www.wipo.int/pctdb/en/wo.jsp?IA=WO2006002854&DISPLAY=DESC 6. TIE ligand homologues , 2006 Godowski, Paul J., Gurney, Austin L., Hillan, Kenneth, Botstein, David, Goddard, Audrey, Roy, Margart, Ferrara, Napoleone, Tumas, Daniel, Schwall, Ralph [0001]The present invention concerns isolated nucleic acid molecules encoding the TIE ligands NL1, NL5, NL8 and NL4, the protein encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the European Patent Office, 2006 7. Antibodies to truncated VEGF-D and uses thereof Achen, Marc G., Stacker, Steven Alan The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the ... Patent record available from the US Patent Office, 2006 46 8. VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor Achen, Marc G., Hughes, Richard A., Stacker, Steven, Cendron, Angela Monomeric monocyclic peptide inhibitors and dimeric bicyclic peptide inhibitors based on exposed loop fragments of a growth factor protein, such as loop 1, 2 or 3 of VEGF-D, and methods of making them are described as well as pharmaceutical compositions ... Patent record available from the US Patent Office, 2006 9. Compounds and uses thereof Semones, Marcus A. The present invention relates to novel compounds and the treatment of mammalian diseases in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred. Patent record available from the US Patent Office, 2006 10. Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using same Achen, Marc Gregory, Stacker, Steven Alan, Renner, Christoph The present invention relates to materials and methods for modulating angiogenesis and lymphangiogenesis. The compositions of the invention provide chimeric and/or humanized VEGF-D antibody substances, antibodies, polypeptides and fragments thereof useful ... Patent record available from the US Patent Office, 2006 11. Methods and compositions for activating or inhibiting vegf-d and vegf-c Mccoll, Bradley, Baldwin, Megan, Stacker, Steven, Achen, Narc Methods for activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a phamarceutical compositions comprising plasmin. Also disclosed are methods for screening for inhibitors of activation of ... Patent record available from the US Patent Office, 2005 12. Transcriptional mediators of blood vessel development and endothelial differentiation Oettgen, Peter, Libermann, Towia This invention relates to methods of modulating the development of blood vessels and/or endothelial cell differentiation in a mammal comprising altering the activity of an Ets transcription factor, which activates vascular specific genes. More ... Patent record available from the US Patent Office, 2005 13. Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue Achen, Marc, Stacker, Steven A method for treating and alleviating disease characterized by the expression of VEGF-D involving screening to find an organism with tumor cells expressing VEGF-D and administering an effective amount of a VEGF-D antagonist; a method for screening for ... Patent record available from the US Patent Office, 2005 14. Methods and compositions for screening for angiogenesis modulating compounds Zhang, Ning, Purchio, Anthony F. The present invention relates to novel promoters, including transcription regulator regions, for the mouse VEGFR-2 receptor, isolated polynucleotides comprising such promoters, nucleic acid constructs comprising such promoters operatively linked to genes ... Patent record available from the US Patent Office, 2005 15. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis Tang, Peng Cho, Sun, Li, Shawver, Laura Kay, Hirth, Klaus Peter, Fong, Annie The present invention relates to methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis. More specifically, this invention relates to methods for treating diseases and disorders, such as rheumatoid arthritis, ... Patent record available from the US Patent Office, 2005 47 16. Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) Siemeister, Gerhard, Haberey, Martin, Thierauch, Karl-Heinz The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of ... Patent record available from the European Patent Office, 2005 17. NL3 TIE receptor tyrosine kinase ligand homologues Fong, Sherman, Ferrara, Napoleone, Goddard, Audrey, Godowski, Paul J., Gurney, Austin L., Hillan, Kenneth, Williams, P. Mickey ( Field of the Invention ) [0001]The present invention concerns isolated nucleic acid molecules encoding novel TIE ligand homologues, the TIE ligand homologue proteins encoded by such nucleic acid molecules, as well as methods and means for making and ... Patent record available from the European Patent Office, 2004 18. Nnl6 tie receptor tyrosine kinase ligand homologues Fong, Sherman, Ferrara, Napoleone, Goddard, Audrey, Godowski, Paul J., Gurney, Austin L., Hillan, Kenneth, Williams, P. Mickey The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligand homologues NL2, NL3 and NL6 (FLS139), the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and ... Patent record available from the European Patent Office, 2004 19. TIE2 RECEPTOR KINASE INHIBITORS FOR TREATING ANGIOGENIC DISEASES SEMONES, Marcus A. ( FIELD OF THE INVENTION ) [0001]The present invention relates to the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred. ( BACKGROUND ... Patent record available from the European Patent Office, 2004 20. Tie ligand homologues Goddard, Audrey, Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2004 21. Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use (II) Siemeister, Gerhard, Haberey, Martin, Thierauch, Karl-Heinz The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of ... Patent record available from the US Patent Office, 2004 22. Antibodies to truncated VEGF-D and uses thereof Achen, Marc G., Stacker, Steven Alan The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the ... Patent record available from the US Patent Office, 2004 23. Novel transcriptional mediators of blood vessel development and endothelial differentiation Oettgen, Peter, Libermann, Towia This invention relates to methods of modulating the development of blood vessels and/or endothelial cell differentiation in a mammal comprising altering the activity of an Ets transcription factor, which activates vascular specific genes. More ... Patent record available from the US Patent Office, 2004 48 24. Antibodies to truncated VEGF-D and uses thereof Achen, Marc G., Stacker, Steven Alan The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the ... Patent record available from the US Patent Office, 2004 25. Novel compounds Adams, Jerry L., Bryan, Deborah L. The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred. Patent record available from the US Patent Office, 2004 26. Composition and method for modulating vasculogenesis or angiogenesis Li, Xuri, Eriksson, Ulf, Carmeliet, Peter, Collen, Desire?apos A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer ... Patent record available from the US Patent Office, 2004 27. Platelet-derived growth factor D Eriksson, Ulf, Aase, Karin, Lee, Xuri, Ponten, Annica, Uutela, Marko, Alitalo, Kari, Oestman, Arne, Heldin, Carl-Henrik PDGF-D, a new member of the PDGF/VEGF family of growth factors, is described, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, ... Patent record available from the US Patent Office, 2004 28. Novel compounds and uses thereof Semones, Marcus A. The present invention relates to novel compounds and the treatment of mammalian diseases in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred. Patent record available from the US Patent Office, 2004 29. Method for activating only the vascular endothelial growth factor receptor-3 and uses thereof Achen, Marc, Stacker, Steven A method for activating only the vascular endothelial growth factor receptor-3 has been created. The method comprises administration of a composition comprising a polypeptide to an animal wherein the composition has the ability to stimulate one or more ... Patent record available from the US Patent Office, 2004 30. NOVEL COMPOUNDS ADAMS, Jerry L., BRYAN, Deborah L. ( FIELD OF THE INVENTION ) [0001]The present invention relates to the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred. ( BACKGROUND ... Patent record available from the European Patent Office, 2003 31. Method to screen ligands using eukaryotic cell display Ashkar, Samy Methods and compositions for the screening and identification of ligands that are expressed and displayed on the outer surface of eukaryotic cells and screening for binding of the ligand to a receptor domain of a chimeric fusion receptor protein which is ... Patent record available from the US Patent Office, 2003 32. Composition and method for modulating vasculogenesis or angiogenesis Li, Xuri, Eriksson, Ulf, Carmeliet, Peter, Collen, Desire A method for modulating vasculogenesis or angiogenesis using the core domain protein of 49 PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical ... Patent record available from the US Patent Office, 2003 33. Vascular endothelial growth factor-like protein from ORF viruses binds and activates mammalian VEGF receptor-2, and uses thereof Wise, Lyn M., Mercer, Andrew A., Savory, Loreen J., Fleming, Stephen B., Stacker, Steven A. The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate ... Patent record available from the US Patent Office, 2003 34. Process and device for making gratings in optical fibres Tallone, Luigi During the process of writing a grating, the fiber is placed in a support which has a surface cut- out such as a V-shaped groove. The side walls of this groove form an angle () of 60° with respect to the direction of propagation of the radiation arriving ... Patent record available from the US Patent Office, 2003 35. 4(HETERO-) ARYL SUBSTITUTED (THIA-/OXA-/PYRA) ZOLES FOR INHIBITION OF TIE-2 STIEBER, Frank, HELLMUTH, Klaus, WALDMANN, Herbert, MAZITSCHEK, Ralph, GIANNIS, Athanassios The inventione relates to a compound of formula (I), wherein V is H or, or, R 1 can be independently H, alkyl, alkenyl, cycloalkyl, heteroalkyl, aryl, heteroaryl,arylalkyl, alkylaryl, N- R 6 R 7 , N- (CO) R 6 R 7 ,N-R 6 (CO) R 7 or N- (CO) -O-R 6 R 7 , R 8 ... Patent record available from the World Intellectual Property Organization (WIPO), 2003 36. COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II) SIEMEISTER, Gerhard, HABEREY, Martin, THIERAUCH, Karl-Heinz [0001]The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of ... Patent record available from the European Patent Office, 2003 37. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003 38. TIE ligands Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules. Patent record available from the US Patent Office, 2003 39. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003 50 40. Method for activating only the vascular endothelial growth factor receptor-3 and uses thereof Achen, Marc, Stacker, Steven A method for activating only the vascular endothelial growth factor receptor-3 has been created. The method comprises administration of a composition comprising a polypeptide to an animal wherein the composition has the ability to stimulate one or more ... Patent record available from the US Patent Office, 2003 41. Novel compounds for inhibition of Tie-2 Stieber, Frank, Hellmuth, Klaus, Waldmann, Herbert, Mazitschek, Ralph, Giannis, Athanassios The present invention provides a method of inhibiting or moderating the kinase activity of tyrosine kinases comprising the administration of a compound represented by formula (1) said kinase in sufficient concentration to inhibit or moderate the enzyme ... Patent record available from the US Patent Office, 2003 42. TIE ligand homologues Goddard, Audrey, Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2003 43. Tie ligand homologues Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules. Patent record available from the US Patent Office, 2003 44. TIE ligand homologues Goddard, Audrey, Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2003 45. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003Platelet-derived growth factor C, DNA coding therefor, and uses thereof Eriksson, Ulf, Fredriksson, Linda PDGF-C, a new member of the PDGF/VEGF family of growth factors, is described, as well as nucleotide sequences, its method of production, antibodies and antagonists. Also disclosed are transfected and transformed host cells expressing same and ... Patent record available from the US Patent Office, 2003 46. NL4 tie ligand homologue Godowski, Paul J., Gurney, Austin L., Hillan, Kenneth, Botstein, David, Goddard, Audrey, Roy, Margaret, Ferrara, Napoleone, Tumas, Daniel, Schwall, Ralph The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5, NL8, and NL4, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2003 51 47. Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereof Wise, Lyn M., Mercer, Andrew A., Savory, Loreen J., Fleming, Stephen B., Stacker, Steven A. The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate ... Patent record available from the US Patent Office, 2003 48. Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use Siemeister, Gerhard, Haberey, Martin, Thierauch, Karl-Heinz The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of ... Patent record available from the US Patent Office, 2003 49. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003 50. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003 51. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003 52. NL3 TIE ligand homologue Goddard, Audrey, Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2003 53. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003 54. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin 52 The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003 55. Secreted and transmembrane polypeptides and nucleic acids encoding the same Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2003 56. NL8 tie ligands homologues Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules. Patent record available from the US Patent Office, 2002 57. Secreted and transmembrane polypeptides and nucleic acids encoding Ashkenazi, Avi J., Baker, Kevin P., Botstein, David A., Desnoyers, Luc, Eaton, Dan L., Ferrara, Napoleone, Fong, Sherman, (...), Zhang, Zemin The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the ... Patent record available from the US Patent Office, 2002 58. METHODS FOR TREATING CANCERS EXPRESSING VASCULAR ENDOTHELIAL GROWTH FACTOR D ACHEN, Marc, Ludwig Institute for Cancer Research, STACKER, Steven, Ludwig Inst. for Cancer Research (BACKGROUND OF THE INVENTION) The invention generally relates to medicaments for treating and alleviating various cancers. The two major components of the mammalian vascular system are the endothelial and smooth muscle cells. The endothelial cells form ... Patent record available from the European Patent Office, 2002 59. NL2 TIE ligand homologue polypeptide Goddard, Audrey, Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS 139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2002 60. Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue Achen, Marc, Stacker, Steven A method for treating and alleviating disease characterized by the expression of VEGF-D involving screening to find an organism with tumor cells expressing VEGF-D and administering an effective amount of a VEGF-D antagonist; a method for screening for ... Patent record available from the US Patent Office, 2002 61. NL3 TIE ligand homologue nucleic acids Goddard, Audrey, Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office,2002 53 62. Tie ligands Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules. Patent record available from the US Patent Office, 2002 63. NL4 tie ligand homologue nucleic acid Godowski, Paul, Gurney, Austin, Hillan, Kenneth J., Botstein, David, Goddard, Audrey, Roy, Margaret, Ferrara, Napoleone, Tumas, Daniel, Schwall, Ralph The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5, NL8, and NL4, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2002 64. VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor Achen, Marc G., Hughes, Richard A., Stacker, Steven, Cendron, Angela Monomeric monocyclic peptide inhibitors and dimeric bicyclic peptide inhibitors based on exposed loop fragments of a growth factor protein, such as loop 1, 2 or 3 of VEGF-D, and methods of making them are described as well as pharmaceutical compositions ... Patent record available from the US Patent Office, 2002 65. Antibodies to truncated VEGF-D and thereof Achen, Marc G., Stacker, Steven Alan The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the ... Patent record available from the US Patent Office, 2002 66. Тie2 antagonist antibodies Holmes, Stephen D., Erickson-Miller, Connie L., Winkler, James D. Tie2 receptor antagonist antibodies, their use in inhibiting angiogenesis and other uses are disclosed. Patent record available from the US Patent Office, 2002 67. Tie ligands Goddard, Audrey, Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL2, NL3 and FLS139, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2002 68. Tie ligand homologues Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules. Patent record available from the US Patent Office, 2002 69. Tie2 agonist antibodies Holmes, Stephen D., Erickson-Miller, Connie L., Winkler, James D. Tie2 receptor agonist antibodies, their use in enhancing angiogenesis and other uses are disclosed. Patent record available from the US Patent Office, 2002 70. Imidazole derivatives ADAMS, Jerry L., JOHNSON, Neil W., MURRAY, Jeffrey H. ( FIELD OF THE INVENTION ) [0001]The present invention relates to the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has 54 occurred and/or where excessive Tie2 receptor activity has occurred. ( BACKGROUND ... Patent record available from the European Patent Office, 2002 71. Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use Siemeister, Gerhard, Haberey, Martin, Thierauch, Karl-Heinz The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)NEGF receptor systems (compound I) and substances interfering with the biological function of ... Patent record available from the European Patent Office, 2002 72. Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) Siemeister, Gerhard, Haberey, Martin, Thierauch, Karl-Heinz The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of ... Patent record available from the European Patent Office, 2002 73. ANTIBODIES TO TRUNCATED VEGF-D AND USES THEREOF ACHEN, Marc G., Ludwig Inst. for Cancer Research, STACKER, Steven Alan, Ludwig Inst. for Cancer Res. [0001]This invention relates to a composition of matter which comprises a monoclonal antibody that is specifically reactive with a polypeptide having the amino acid sequence as set forth in Figure 1 (SEQ ID NO:1). The antibody includes immunoreactive ... Patent record available from the European Patent Office, 2001 74. Methods for treating various cancers expressing vascular endothelial growth factor D, for screening for a neoplastic disease and for maintaining vascularization of tissue Achen, Marc, Stacker, Steven A method for treating and alleviating melanomas and various cancers characterized by the expression of VEGF-D by the tumor, the method comprising screening to find an organism with tumor cells expressing VEGF-D and administering an effective amount of a ... Patent record available from the US Patent Office, 2001 75. Methods and compositions for screening for angiogenesis modulating compounds Ning, Zhang, Contag, Pamela Reilly, Purchio, Anthony F. The present invention relates to novel transcription control elements, including promoters, derived from angiogenesis-related genes, particularly the mouse VEGF gene, the mouse VEGFR-2 receptor gene, and the mouse Tie2 gene. Also disclosed are isolated ... Patent record available from the US Patent Office, 2001 76. TARGETING CONSTRUCTS AND TRANSGENIC ANIMALS PRODUCED THEREWITH ZHANG, Ning The present invention teaches targeting constructs and methods of use thereof for creating transgenic animals in which at least one single-copy, non-essential gene is replaced with a reporter expression cassette, for example, a luciferase gene operably Patent record available from the World Intellectual Property Organization (WIPO), 2001 77. VASCULAR ENDOTHELIAL GROWTH FACTOR-LIKE PROTEIN FROM ORF VIRUS NZ10 BINDS AND ACTIVATES MAMMALIAN VEGF RECEPTOR-2 WISE, Lyn, M., Virus Research Unit, MERCER, Andrew, A., Virus Research Unit, SAVORY, Loreen, J., Virus Research Unit, FLEMING, Stephen, B., Virus Research Unit, STACKER, Steven A., Angiogenesis Lab., Ludwig Inst [0001]This invention relates to viral vascular endothelial growth factor-like proteins which binds and activates the mammalian VEGF receptor-2 to induce vascular permeability of endothelial cells, and in particular to pharmaceutical and diagnostic ... Patent record available from the European Patent Office, 2001 55 78. TIE2 AGONIST ANTIBODIES HOLMES, Stephen D., ERICKSON-MILLER, Connie L., WINKLER, James D. ( Field of the Invention ) [0001]This invention relates to agonist monoclonal antibodies (mAb) that bind to the Tie2 receptor and to the use of such antibodies for therapeutic purposes. ( Background of the Invention ) [0002]Angiogenesis or ... Patent record available from the European Patent Office, 2001 79. VEGF-D/VEGF-C/VEGF PEPTIDOMIMETIC INHIBITOR ACHEN, Marc, G., HUGHES, Richard, A., STACKER, Steven, CENDRON, Angela Monomeric monocyclic peptide inhibitors and dimeric bicyclic peptide inhibitors based on exposed loop fragments of a growth factor protein, such as loop (1, 2 or 3) of VEGF-D, and methods of making them are described as well as pharmaceutical compositions ... Patent record available from the World Intellectual Property Organization (WIPO), 2001 80. NOVEL COMPOUNDS ADAMS, Jerry, L., JOHNSON, Neil, W., MURRAY, Jeffrey, H. The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred. Patent record available from the World Intellectual Property Organization (WIPO), 2001 81. TIE RECEPTOR TYROSINE KINASE LIGAND HOMOLOGUES FONG, Sherman, FERRARA, Napoleone, GODDARD, Audrey, GODOWSKI, Paul J., GURNEY, Austin L., HILLAN, Kenneth, WILLIAMS, P., Mickey ( Field of the Invention ) [0001]The present invention concerns isolated nucleic acid molecules encoding novel TIE ligand homologues, the TIE ligand homologue proteins encoded by such nucleic acid molecules, as well as methods and means for making and ... Patent record available from the European Patent Office, 2000 82. Nucleic acids encoding NL-3 Fong, Sherman, Ferrara, Napoleone, Goddard, Audrey, Godowski, Paul J., Gurney, Austin L., Hillan, Kenneth, Williams, P. Mickey The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligand homologues NL2, NL3 andNL6 (FLS139), the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and ... Patent record available from the US Patent Office, 2000 83. Tie ligand homologues Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5, NL8, and NL4, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein ... Patent record available from the US Patent Office, 2000 84. TIE LIGAND HOMOLOGUES GODOWSKI, Paul J., GURNEY, Austin L., HILLAN, Kenneth, BOTSTEIN, David, GODDARD, Audrey, ROY, Margaret, FERRARA, Napoleone, TUMAS, Daniel, SCHWALL, Ralph ( Field of the Invention ) [0001]The present invention concerns isolated nucleic acid molecules encoding novel TIE ligand homologues, the TIE ligand homologue proteins encoded by such nucleic acid molecules, as well as methods and means for making and ... Patent record available from the European Patent Office, 2000 85. ANTIBODIES TO TRUNCATED VEGF-D AND USES THEREOF ACHEN, Marc G., STACKER, Steven, Alan The invention is based on the isolation of antibodies that were made to a polypeptide having the amino acid sequence for a truncated VEGF-D. One of these antibodies can interfere with the activity of VEGF-D mediated by VEGFR-2 and interfere with the ... Patent record available from the World Intellectual Property Organization (WIPO), 2000 56 86. VASCULAR ENDOTHELIAL GROWTH FACTOR-LIKE PROTEIN FROM ORF VIRUS NZ2 BINDS AND ACTIVATES MAMMALIAN VEGF RECEPTOR-2 WISE, Lyn M., MERCER, Andrew A., SAVORY, Loreen J., FLEMING, Stephen B., STACKER, Steven A. The invention is based on the discovery that a viral VEGF-like protein from the orf virus strain NZ2 and from the orf virus strain NZ10 is capable of binding to the extracellular domain of the VEGF receptor-2 to form bioactive complexes which mediate ... Patent record available from the World Intellectual Property Organization (WIPO), 2000 87. TIE2 ANTAGONIST ANTIBODIES HOLMES, Stephen, D. Tie2 receptor antagonist antibodies and their use in inhibiting angiogenesis are disclosed. Patent record available from the World Intellectual Property Organization (WIPO), 2000 88. TIE2 AGONIST ANTIBODIES HOLMES, Stephen, D. Tie2 receptor agonist antibodies, their use in enhancing angiogenesis and other uses are disclosed. Patent record available from the World Intellectual Property Organization (WIPO), 2000 89. TIE LIGAND HOMOLOGUES GODOWSKI, Paul, J., GURNEY, Austin, L., HILLAN, Kenneth, BOTSTEIN, David, GODDARD, Audrey, ROY, Margaret, FERRARA, Napoleone, TUMAS, Daniel, SCHWALL, Ralph The present invention concerns isolated nucleic acid molecules encoding the TIE ligands NL1, NL5, NL8 and NL4, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules. Patent record available from the World Intellectual Property Organization (WIPO), 1999 90. TIE RECEPTOR TYROSINE KINASE LIGAND HOMOLOGUES FONG, Sherman, FERRARA, Napoleone, GODDARD, Audrey, GODOWSKI, Paul, J., GURNEY, Austin, L., HILLAN, Kenneth, WILLIAMS, P., Mickey The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligand homologues NL2, NL3 and NL6 (FLS139), the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and ... Patent record available from the World Intellectual Property Organization (WIPO), 1999 91. Tie ligands homologues Godowski, Paul J., Gurney, Austin L. The present invention concerns isolated nucleic acid molecules encoding the novel TIE ligands NL1, NL5 and NL8, the proteins encoded by such nucleic acid molecules, as well as methods and means for making and using such nucleic acid and protein molecules. Patent record available from the US Patent Office, 1999